OTC + BC MACS Comprehensive Counselling Atlas
This comprehensive atlas combines the original nine GI/oral topics, nine MSK/infectious disease/dermatology chapters and nine newly added HEENT/respiratory/ocular chapters drawn from all uploaded lectures, including the dedicated Acne.pdf. Total 27 conditions/clinical modules. Regimens are condensed study examples; check the current Canadian monograph before counselling or prescribing.
Current BC MACS scope relevant here: Canker sores (topical), cold sores (antiviral category), GERD/dyspepsia (acid-reducing), localized musculoskeletal pain (NSAID category), uncomplicated UTI (antibiotics), acne and dermatitis (topical), onychomycosis (topical), allergic rhinitis (intranasal / oral antihistamine / ophthalmic categories) and conjunctivitis (ophthalmic). Sinusitis, pharyngitis, cough/cold, blepharitis, hordeolum/chalazion and dry eye are not distinct BC MACS diagnoses. Specialist medicines are included for pharmacotherapy context only. Students do not independently prescribe.
Dose rule: Typical example doses are for education, not patient-specific prescriptions. Check current Canadian DIN, actual brand formulation, pregnancy/breastfeeding status, renal/hepatic function, age/weight, drug interactions and prescriber authority. "Not specified" means the lecture did not provide a safe universal regimen.
ONE-GLANCE TRIAGE MATRIX
| Complaint | BC status | Recognition | Referral trigger | Review |
|---|---|---|---|---|
| Canker sores | Topical MACS | Intrabuccal round ulcers with pale centre | >14 d, major, recurrent, systemic/immunosuppressed | 7 d |
| Cold sores | Oral/topical MACS | Tingling → grouped lip vesicles/crust | Eye involvement, systemic, immunosuppressed | 7 d |
| Dry mouth | OTC; Rx outside MACS | Dry tongue, thick saliva, dysphagia | Persistent/unexplained, dental/systemic disease | 1 week |
| Gas | OTC | Belching, flatulence, post-food bloat | Pain, altered bowel habits, persistent/new >40 | 1–2 wk |
| GERD | Acid-reduction MACS | Retrosternal burning/regurgitation | Chest pain, bleed, dysphagia, weight loss | 2–4 wk |
| Dyspepsia | Acid-reduction MACS | Epigastric pain, early satiety/fullness | Alarm symptoms; H. pylori evaluation | 2–4 wk |
| Constipation | OTC; Rx outside MACS | Hard/rare stool, strain, incomplete | Obstruction, bleeding, new >50, >2 wk | Days; 2–4 wk |
| Diarrhea / TD | OTC; ABx outside MACS | ≥3 loose stools/day | Blood, fever, dehydration, recent ABx | 24–48 h |
| Nausea/vomiting | OTC; Rx outside MACS | Emesis, retching; identify cause | Blood, DKA/obstruction, dehydration, child | Hours–48 h |
| Localized MSK pain | NSAID MACS | Local soft tissue or peripheral joint pain | Trauma/deformity, unable bear weight, fever/hot joint | 3–7 d |
| Uncomplicated cystitis | Antibiotic MACS | Dysuria, frequency, urgency; no systemic sx | Fever/flank pain, pregnancy, complex illness | 48 h |
| Head lice | OTC only | Live moving lice, scalp itch | Scalp infection, failure after correct courses | 7–10 d |
| Scabies | OTC/clinician | Nocturnal itch, burrows, household cases | Crusted/immunocompromised, infants, atypical | 1–4 wk |
| Rosacea | Rx external MACS | Centrofacial erythema, no comedones | Eye pain/vision changes, rhinophyma | 8–12 wk |
| Onychomycosis | Topical MACS | Discoloured, thick, crumbly nail | Matrix or extensive disease, melanoma risk | 3–12 mo |
| Atopic dermatitis | Topical MACS | Itchy dry relapsing eczema | Infection/herpeticum, severe widespread | 5–14 d |
| Contact dermatitis | Topical MACS | Exposure pattern, eczematous rash | Severe bullae, >20% BSA, sensitive sites | 5–7 d |
| Acne vulgaris | Topical MACS | Comedones ± papules/pustules | Scarring, nodules, severe distress | 8–12 wk |
| Sinusitis | OTC; antibiotics other prescriber | PODS + viral <10 d vs bacterial ≥10 d/double sickening | Eye swelling, vision loss, severe headache/neck stiffness | 48–72 h |
| Allergic rhinitis | BC MACS intranasal / H1 / ophthalmic | Nasal itch/sneeze, clear discharge, allergic trigger | Unilateral bleeding, refractory, severe breathing/eye symptoms | 3–7 d |
| Pharyngitis | OTC; antibiotics other prescriber | Viral cough/coryza vs GAS fever, exudate, no cough | Stridor, drooling, trismus, unilateral swelling | 48–72 h |
| Common cold | OTC only | Sore throat → rhinorrhea → cough; viral | Breathing difficulty, fever >3 d, worsening | 48–72 h |
| Cough | OTC only | Dry vs productive; postviral possible | Dyspnea, hemoptysis, COPD flare, >3 wk | 48–72 h |
| Conjunctivitis | BC MACS ophthalmic | Purulent bacterial; watery viral; itch allergic | Contact lens painful red eye, photophobia, vision loss | 24–48 h |
| Blepharitis | OTC lid care; Rx other prescriber | Chronic bilateral crusts vs oily/foamy tears | Visual change, pain, persistent despite care | 1–2 wk |
| Hordeolum/chalazion | OTC care | Tender acute stye vs slow sterile lump | Spreading eyelid infection, visual change | 2–7 d |
| Dry eye | OTC lubricants; Rx outside MACS | Gritty burning/fluctuating blur, paradoxical tears | Pain, photophobia, contact lens red eye | 3–5 d |
01 | Aphthous ulcers / canker sores
BC MACS: topical Schedule I drugs for eligible minor oral ulcersLecture basis: GI 14 slides 5–23Risk factors / causes
Female sex; family history; age <40; immune dysfunction; deficient B1/B2/B6/B12, iron, folate or zinc; stress; oral trauma; hormonal change; recent smoking cessation; SLS toothpaste; certain foods/additives; ACEi, beta-blockers, NSAIDs, immunosuppressants.
Clinical presentation
Minor (70–95%): 1–5 painful round/oval ulcers <1 cm with pale/yellow fibrin centre and erythematous halo, NON-keratinized inner cheeks/lips, underside of tongue, floor/soft palate; 7–14 d, no scar. Major: >1 cm, deep, 1–10, weeks–months and scars. Herpetiform: ≥10 pinpoint 1–3-mm lesions, may coalesce; NOT HSV. Noncontagious, no external lip vesicles.
When to REFER / exclude self-care
Major/herpetiform lesions; >14 d or scarring; marked pain limiting hydration/intake; frequent ≥6–12 episodes/year; first occurrence >30; immunosuppression/HIV/IBD; fever or extraoral/genital/ocular lesions; hard or indurated suspicious lesion; unusual hard-palate/gingival lesions; suspected drug reaction or systemic disease (Behçet, Crohn, malignancy), uncertain diagnosis.
Complications + goals
Complications: Poor eating/dehydration, rarely weight loss; secondary infection; underlying systemic disease missed.
Goals: Comfort in 1–2 d; normal oral intake; healing by 14 d; avoid recurrence and infection.
| Drug / strength / status | Dose · frequency · duration | Contraindications / precautions | Adverse effects / interactions | What to monitor |
|---|---|---|---|---|
| Acetaminophen [OTC] | 325/500-mg oral tabs | 325–650 mg q4–6h or 500–1,000 mg q6h PRN pain for several days; prudent self-care max 3 g/day adult (lower with liver disease/low weight). | Severe liver disease; duplicate combination acetaminophen; chronic heavy alcohol. | Nausea uncommon; dose-dependent hepatotoxicity with overdose; alcohol/warfarin (regular high use). | Pain at 24–48 h; total acetaminophen from all products; stop as ulcer heals. |
| Benzocaine [OTC] | multiple gels, commonly 10–20% | Dry ulcer; thin application up to 4 times/day before meals/bedtime, up to 7 d; no food/drink ~30 min. Exact formulation label governs. | Under 2 years; prior methemoglobinemia, benzocaine/ester-anesthetic allergy; avoid large or damaged area. | Stinging, contact allergy; rare life-threatening methemoglobinemia (blue/gray skin, dyspnea)—urgent care; few systemic DDIs. | Immediate temporary relief (~20–45 min); stop for irritation/cyanosis. |
| Lidocaine viscous/topical [formulation-dependent] | 2% | Local small-amount application as specifically directed by product/prescriber; dose not supplied in lecture—verify maximum by age/weight. | Young children, swallowing impairment; excess dosing; hepatic disease or cardiac conduction issues. | Numbness, burns/bites, aspiration and systemic toxicity if swallowed; antiarrhythmics add toxicity. | Swallowing and oral injury; do not eat while numb. |
| Hydroxypropylcellulose (Zilactin) / carboxymethylcellulose (Orabase) [OTC protective paste] | Dry area then dab a small coating at bedtime and as needed; avoid food/drink for 30 min; use until healing. | Product allergy; check age-specific label. | Sticky sensation, local irritation; minimal DDIs. | Comfort and ability to eat; worsening irritation. |
| Triamcinolone acetonide 0.1% dental paste (Oracort) [MACS Rx] | Dry surface; press/dab small amount after meals 2–3 times/day and at bedtime; begin early; generally ≤7 d per lecture. Do NOT rub in. | Suspected herpes, thrush, other oral infection or untreated bacterial infection; corticosteroid hypersensitivity. | Local irritation, candidiasis/secondary infection; systemic effects unlikely with small area; other immunosuppressants increase infection concern. | Pain 1–2 d, smaller ulcer by day 7, fully healed ≤14 d; examine for thrush, refer if no improvement by 7 d. |
| Vitamin B12 [OTC nutritional supplement] | sublingual 1,000 micrograms | 1,000 micrograms SL once daily for ≥4 months as a trial for frequent recurrent aphthae; NOT acute analgesia. | Investigate significant deficiency or underlying malabsorption; not a substitute for diagnostic workup. | Generally tolerated; clinically important interactions uncommon. | Episode frequency over 4–6 months; check B12/iron/folate if deficiency suspected. |
02 | Herpes labialis / cold sores
BC MACS: topical or oral Schedule I antivirals; OTC supportive treatmentsLecture basis: GI 14 slides 24–55Risk factors / causes
HSV-1 usually (sometimes HSV-2). Previous exposure, close contact and shedding; triggers: UV light, fever/illness, trauma, stress, menstrual hormonal changes, immunosuppression. Recurrent >6/y suggests need to reassess.
Clinical presentation
Prodrome tingling/burning/itching then clustered papules → vesicles on lip/vermilion/perioral skin → ulcer/crust in ~7–14 d. May sting. Primary infection may cause fever, diffuse gingivostomatitis, painful nodes, poor intake. Contagious from prodrome until completely healed.
When to REFER / exclude self-care
Age <12 per lecture referral rule; immunocompromised; possible ocular involvement (RED EYE, pain, photophobia: urgent same-day); extensive intraoral/pharyngeal disease; fever/systemic illness, dehydration; spreading beyond lip, atypical/uncertain diagnosis; severe purulence/bleeding; >14 d; not improving by 7 d; >6 recurrences/y.
Complications + goals
Complications: HSV keratitis, eczema herpeticum, secondary bacterial infection, dehydration in primary gingivostomatitis, spread to others.
Goals: Minimize pain and outbreak by ~0.5–2 d if treated VERY early; prevent spread; consider suppression only for frequent episodes.
| Drug / strength / status | Dose · frequency · duration | Contraindications / precautions | Adverse effects / interactions | What to monitor |
|---|---|---|---|---|
| Docosanol 10% cream (Abreva) [OTC] | Apply thin layer 5 times/day ~q3–4h beginning within 12 h of prodrome; typically up to healing, 5–10 d (check package maximum). | Product hypersensitivity; evidence limited later in established crusts. | Local stinging/burning, headache; systemic DDIs unlikely. | Lesion pain/size each day; expect modest time reduction only. |
| Acyclovir 5% cream (Zovirax) [MACS Rx] | Apply 5 times/day at first prodrome, ideally within 1 h, for 4 d. Cream preferred to ointment in lecture. | Known allergy; avoid eyes/intraoral use unless product specifically intended. | Local rash/irritation; minimal systemic DDIs. | Healing/pain by days 3–7; refer if worsening or >14 d. |
| Acyclovir 5% + hydrocortisone 1% cream [MACS Rx, if available] | Apply 5 times/day for 5 d, starting immediately at prodrome; verify Canadian availability. | Avoid bacterial/fungal facial skin infection or eye; uncertain lesion diagnosis. | Local irritation, theoretical steroid-associated infection; minimal DDIs. | Resolution and appearance of new vesicles, 3–7 d. |
| Acyclovir PO [MACS Rx] | 200-/400-mg tablets | RECURRENT: 400 mg PO 5 times/day for 5 d. PRIMARY moderate–severe: 200 mg 5 times/day OR 400 mg TID for 7 d (lecture regimens). | Renal impairment/dehydration—adjust; allergy; verify need for systemic treatment. | Headache, nausea; renal crystal nephropathy/neurotoxicity at excessive dose/renal impairment; nephrotoxins (NSAIDs) increase risk. | Ensure hydration; check renal function where indicated; symptoms days 3–7. |
| Valacyclovir PO [MACS Rx] | 500-mg, 1-g tablets | RECURRENT: 2 g PO BID for ONE day (two doses 12 h apart; take immediately). PRIMARY: 1 g PO BID x 7 d (lecture). | Renal dose adjustment, dehydration, severe immunosuppression outside simple MACS scenario. | Headache, nausea; rare renal/neurotoxicity; caution concomitant nephrotoxins. | Lesion/healing within 7–14 d; check renal dosing. |
| Famciclovir PO [MACS Rx] | 250-/500-mg tablets | RECURRENT: 1,500 mg PO once OR 750 mg PO BID x 1 d. PRIMARY: 250 mg TID OR 500 mg BID x 7 d (lecture). | Renal impairment requires adjustment; pregnancy/lactation data more limited. | Headache, nausea, dizziness; possible nephrotoxic drug coexposure concern. | Pain and days to resolution, check renal function if indicated. |
| Topical benzocaine/lidocaine/pramoxine [OTC symptom relief] | Apply small amount to intact surrounding skin per specific label PRN for brief pain relief; strengths/intervals vary by product. | Local anesthetic allergy; avoid mouth/eyes; benzocaine methemoglobinemia caution. | Burning, sensitization; excessive dosing toxicity; few systemic interactions. | Comfort; any rash/systemic effects. |
| Petrolatum / zinc oxide / cocoa-butter barrier [OTC] | Apply thin layer PRN to prevent cracking until crust resolves. | Topical hypersensitivity. | Rare irritation; no material DDIs. | Cracking, secondary infection. |
| Zinc sulfate (Lipactin) / propolis 3% / lysine [NHP] | Zinc topical q2h x 5 d early; propolis topical 4–6 times/day; lysine prevention 500–1,000 mg PO QID per slide (low-quality evidence). | Avoid propolis with bee/pollen allergy or asthma; oral lysine caution renal/hepatic impairment and pregnancy. | Contact reaction, uncertain efficacy; lysine long-term data limited. | Do not replace antiviral; refer if course atypical. |
| Acyclovir/valacyclovir chronic suppression [clinician-directed—not routine MACS episodic visit] | Lecture preventive examples: acyclovir 200 mg QID or 400 mg BID x 4 months; valacyclovir 500 mg daily x 4 months; reassess need. | Frequent recurrence should prompt clinician assessment; renal adjustment. | Headache/nausea, possible nephrotoxicity; monitor renal risk. | Recurrence count over 4 months; reassess stopping/long-term plan. |
03 | Xerostomia / dry mouth
OTC counselling; systemic sialagogues are NOT a BC MACS indicationLecture basis: GI 14 slides 56–75Risk factors / causes
Older age/polypharmacy, anticholinergic burden (1st-gen antihistamines, oxybutynin, scopolamine), TCAs, paroxetine/venlafaxine/bupropion, antipsychotics, opioids, diuretics; diabetes, hypothyroidism, Sjögren, CKD/dehydration, HIV; head-neck radiation; tobacco, caffeine, alcohol, cannabis; mouth breathing or CPAP.
Clinical presentation
Dry/sticky mouth, thick stringy saliva, thirst, dysgeusia, halitosis, dysphagia for dry food, speaking difficulty; dry fissured lips/tongue, angular cheilitis, increased caries; dry eyes suggest Sjögren.
When to REFER / exclude self-care
Persistent/unexplained symptoms; severe dysphagia, weight loss, dental infection/thrush; dry eyes/systemic autoimmune symptoms; head-neck radiotherapy; medication changes needed; swelling/mass, oral ulcer, dehydration. Refer dentist for new caries risk.
Complications + goals
Complications: Dental caries/periodontitis, oral candidiasis, impaired food intake/nutrition, sleep disturbance, speech/swallowing difficulty.
Goals: Increase comfort/salivary function, prevent dental disease/candidiasis; address drug or disease cause.
| Drug / strength / status | Dose · frequency · duration | Contraindications / precautions | Adverse effects / interactions | What to monitor |
|---|---|---|---|---|
| Artificial saliva (Biotène, Moi-Stir, Mouth-Kote, Oralbalance) [OTC] | spray/gel/rinse | Apply as label directs, especially before meals/bed and PRN; often lasts ~1 h. Formulations vary (carboxymethylcellulose, enzymes, mucopolysaccharides). | Product ingredients allergies; check sugar/acid composition and dental risk. | Usually local irritation or unpleasant taste; negligible interactions. | Comfort after each use; oral mucosa/caries; review at 1 week. |
| Sugar-free xylitol / sorbitol / mannitol gum or lozenges [OTC] | Chew/suck frequently PRN while awake if salivary glands functional; strength varies widely by brand. | Choking risk, chewing problems; caution sorbitol in diarrhea. | Polyol-related gas/bloating/diarrhea; minimal drug interactions. | Saliva benefit, GI tolerance, oral hygiene. |
| Citric acid 5% glycerin / lemon-glycerin swabs [OTC] | Use PRN per product; not preferred for repeated use if dental enamel vulnerable. | Erosion/caries, mucosal ulceration; sensitive mouth. | Stinging, enamel risk from acid; no significant DDIs. | Oral irritation, tooth sensitivity. |
| Anetholtrithione 25 mg tablet (Sialor) [non-MACS product; access/availability check] | 25 mg PO TID before meals per lecture; duration not specified—reassess after 1–2 weeks. | Suspected bile duct obstruction or hepatic disease requires prescriber review; verify marketed status. | Abdominal discomfort, flatulence; long-term safety uncertain; DDIs not well characterized. | Symptom response, GI intolerance. |
| Pilocarpine (Salagen) 5-mg oral [Rx, NOT MACS] | 5 mg PO TID–QID; lecture max 30 mg/day. Specialist/prescriber for Sjögren or post-radiotherapy xerostomia. | Uncontrolled asthma, acute iritis/narrow-angle glaucoma, significant cardiopulmonary disease; GI obstructive disorders; caution older adults. | Sweating, nausea, urinary frequency, lacrimation, dizziness, diarrhea, brady/tachyarrhythmia; anticholinergics oppose effect, beta blockers may add bradycardia. | Saliva/comfort and sweating/BP/HR in first days–weeks; dental surveillance. |
04 | Bloating, belching and intestinal gas
OTC only (no gas-specific MACS indication)Lecture basis: GI 09 slides 4–17Risk factors / causes
Aerophagia: eating rapidly, chewing gum, smoking, carbonated beverages; fermentable FODMAPs/oligosaccharides, lactose maldigestion, high-fibre diet; constipation/IBS/celiac; some drugs changing microbiome, digestion or GI motility.
Clinical presentation
Belching, passing flatus, episodic bloating, distention and mild cramping linked to meals. Lactose: gas, cramping, diarrhea after dairy; oligosaccharides: symptoms after beans, legumes, onions or some grains.
When to REFER / exclude self-care
Severe/persistent/frequent new symptoms, sudden altered bowel habits, new onset >40, weight loss, fever, vomiting, bleeding, severe focal pain, persistent diarrhea/constipation, signs of obstruction, known GI disease.
Complications + goals
Complications: Most transient; if persistent may signify GI pathology; dehydration or nutritional restriction from unnecessary avoidance.
Goals: Reduce meal-related discomfort and bloating, identify dietary trigger, preserve adequate diet.
| Drug / strength / status | Dose · frequency · duration | Contraindications / precautions | Adverse effects / interactions | What to monitor |
|---|---|---|---|---|
| Simethicone [OTC] | 80-/125-/180-mg forms | 80–160 mg PO after meals/at bedtime up to QID PRN per lecture; follow formulation label; short trial ~1–2 weeks. | Hypersensitivity; assess for obstruction instead of masking severe distention. | Minimal absorption, adverse effects/DDIs negligible; evidence for isolated intestinal gas weak. | Bloating/distention after 3–7 d; stop if no benefit. |
| Lactase enzyme [OTC] | 9,000 FCC units | Take 9,000 FCC units with first bite of lactose-containing food or immediately before; repeat with separate meals (product-specific). | Milk protein allergy is NOT lactose intolerance; cannot prevent allergic reactions. | Minimal adverse effects/DDIs; high lactose loads can still cause symptoms. | Symptoms after dairy exposure over 1–2 weeks; diet tolerance. |
| Alpha-galactosidase [OTC] | 150–450 GalU | Take 150–450 GalU with FIRST bite of gas-forming food (beans, vegetables, whole grains); each triggering meal. | Rare enzyme allergy; product source ingredients (e.g., Aspergillus) and galactosemia considerations. | Possible hypersensitivity; efficacy variable; minimal known DDIs. | Bloating/flatulence after trigger foods over 1–2 weeks. |
| Bismuth subsalicylate [OTC] | 262-mg tablet | 524 mg PO every 30–60 min PRN, maximum 8 DOSES = 16 ×262-mg tabs per 24 h; short term ≤2 d for acute GI symptoms. Less useful for uncomplicated gas. | Salicylate allergy, active bleeding/ulcer, anticoagulants, pregnancy, children/teens with viral illness; renal disease. | Black tongue/stool, nausea; bleeding (warfarin, DOACs, antiplatelets, NSAIDs); interaction with tetracyclines. | GI symptoms and black stools vs genuine bleeding; stop if no response. |
| Probiotics [OTC] | strain/product variable | No universal evidence-based gas dose or duration; use manufacturer regimen only if individual indication established. | Significant immunocompromise/central lines/high-risk medically ill patients—avoid without clinician input. | Transient gas; very rare invasive infection; no routine DDIs. | Document exact strain, measure response at 1–2 weeks. |
05 | GERD / uncomplicated heartburn
BC MACS: gastric acid-reducing Schedule I medicinesLecture basis: GI 11 slides 6–53Risk factors / causes
Obesity, pregnancy, smoking, hiatal hernia, older age, stress; large/fatty meals, caffeine, alcohol, chocolate, peppermint, acid foods. Drugs: CCB, nitrates, anticholinergics, benzodiazepines, β2-agonists, GLP-1RA, opioids; pill esophagitis from bisphosphonates, iron, KCl, doxycycline, NSAIDs.
Clinical presentation
Characteristic RETROSTERNAL burning + acid regurgitation, worsened after meals/lying/bending, +/- water brash, belching, cough/hoarseness. Infrequent <2 days/week; frequent ≥2. Severe disrupts ADLs or sleep.
When to REFER / exclude self-care
EMERGENCY for suspected cardiac chest pain. Other: dysphagia/odynophagia; GI bleed/melena/anemia; weight loss; mass; recurrent vomiting; cancer family history; >50 new/worsening; <18 under lecture PPMAC criteria; nocturnal/severe, respiratory symptoms, uncertain diagnosis; failed adequate PPI, relapse <90 days.
Complications + goals
Complications: Erosive esophagitis, peptic stricture, Barrett esophagus, esophageal cancer, dental erosion; sleep impairment.
Goals: Relief 2–7 d, symptom remission during 4–8 weeks; heal esophagitis where present; lowest effective maintenance therapy if objectively indicated.
| Drug / strength / status | Dose · frequency · duration | Contraindications / precautions | Adverse effects / interactions | What to monitor |
|---|---|---|---|---|
| Calcium carbonate (Tums) [OTC] | commonly 500/750/1,000-mg chewables | Product-dependent: e.g. 500–1,000 mg calcium carbonate chewed PRN for infrequent symptoms; do not exceed label/day; short-term, often a few days. | Hypercalcemia, nephrolithiasis, excessive calcium supplementation, severe renal disease; distinguish elemental Ca. | Constipation, belching; milk-alkali syndrome with chronic large doses. Chelates levothyroxine, tetracyclines, quinolones, iron, bisphosphonates: separate 2 h before or 4–6 h after as appropriate. | Relief within minutes; frequency of use, constipation; avoid daily reliance. |
| Magnesium hydroxide/aluminum hydroxide antacids [OTC] | liquid/tablet varies | Per product label PRN after meals/bed; doses depend on formulation; lecture does not provide a universal mg dose. | Avoid Mg or Al in renal impairment; Al causes hypophosphatemia prolonged exposure; elderly caution. | Mg diarrhea; Al constipation, belching; same chelation/absorption DDIs as other antacids. | Symptoms within minutes, diarrhea/constipation and renal risk. |
| Sodium bicarbonate / ASA-containing effervescent antacid (e.g. Alka-Seltzer) [OTC] | Formulation-specific label PRN; not preferred for routine GERD. | Heart failure, HTN, edema, cirrhosis, CKD, pregnancy due sodium; ASA-containing types: anticoagulation, GI bleed, aspirin allergy. | Bloating/metabolic alkalosis, sodium load, GI bleeding; NSAID/anticoagulant interactions. | Fluid status and bleeding; recommend alternative for most. |
| Alginate + antacid (e.g. Gaviscon) [OTC] | strengths vary by Canadian product | Chew/tablet or liquid after meals and at bedtime per exact label; useful for meal-triggered symptoms; short PRN course. | Sodium-content caution in HF/CKD; antacid mineral warnings depend on formulation. | Minor bloating, calcium/magnesium DDIs if included; separate from other drugs. | Postprandial symptom improvement shortly after administration. |
| Famotidine [OTC/Rx] | 10-,20-,40-mg tabs | OTC 10–20 mg PO once or BID PRN for symptoms/anticipated trigger. Rx 20–40 mg BID for selected cases. PPMAC infrequent: trial on demand or BID x 2 weeks; reassess. | Renal impairment: reduce dose/extend interval; allergy. | Headache, dizziness, constipation/diarrhea; acid-dependent drug absorption (azole antifungals, iron), possible levothyroxine effect; H2RA tolerance in 2–6 weeks. | Relief hours after dose; symptom days 2–7, renal risk, need for regular use. |
| Ranitidine / nizatidine / cimetidine [historical/alternative H2RA] | Lecture: ranitidine OTC 75–150 mg daily, Rx 150 mg BID or 300 mg daily; nizatidine 150 mg BID; cimetidine 800 mg daily or 600 mg BID or 300 mg QID. Verify current Canadian marketed status before use; FAMOTIDINE usually preferred. | All require renal consideration; cimetidine additionally liver disease and interacting medications; ranitidine has NDMA testing history. | Cimetidine inhibits multiple CYP enzymes (warfarin, phenytoin, theophylline etc), antiandrogenic effects; headache/GI effects. | Reassess quickly; not automatically substitute old slide brands. |
| Omeprazole [OTC/Rx] | 20-mg capsules | 20 mg PO daily 30–60 min before breakfast x 4 weeks, extend x 4 more weeks only if appropriate. Not rapid PRN. | Alarm symptoms/possible malignancy; severe liver disease; assess high-risk ongoing therapy. | Headache, diarrhea, constipation; CYP2C19 inhibits clopidogrel activation; may raise phenytoin/warfarin/citalopram exposure; reduces acid-dependent absorption (azole antifungals, iron, levothyroxine). | Reassess 2–4 weeks, relief days 2–7; long-term need and Mg/B12/renal issues if maintained. |
| Esomeprazole [OTC/Rx] | 20/40 mg | 20 or 40 mg PO daily 30–60 min before meal x 4–8 weeks depending case. | As for PPI; consider contraindications to acid suppression. | As PPI; same clinically relevant clopidogrel CYP2C19 interaction as omeprazole. | Symptom response 2–4 weeks; deprescribe when resolved. |
| Pantoprazole (Na or Mg) [MACS Rx] | 40 mg | 40 mg PO daily 30–60 min before a meal x 4 weeks (option continuation to 8 weeks depending severity); can be selected when CYP2C19 interaction concern. | As for PPI; watch multiple-drug regimens. | Headache/diarrhea, rare AIN and hypomagnesemia long term; acid-dependent absorption DDIs. | Response 2–4 weeks; reassess need at end of course. |
| Lansoprazole [MACS Rx] | 30 mg | 30 mg PO daily 30–60 min before breakfast x 4–8 weeks. | PPI contraindications; caution in severe liver disease. | Class GI/CNS ADRs; acid-suppression DDIs. | Relief in days, reassess 2–4 weeks. |
| Rabeprazole [MACS Rx] | 20 mg | 20 mg PO daily before meal x 4–8 weeks. | PPI cautions. | GI/CNS effects; acid-suppression DDIs. | Response 2–4 weeks. |
| Dexlansoprazole [MACS Rx when appropriate] | 30/60 mg | 30 or 60 mg PO daily x 4–8 weeks depending presentation and product monograph; dual-release, less meal-dependent. | PPI cautions, coverage restrictions. | Class ADRs/DDIs, possibly reduced acid-dependent drug absorption. | Response at 2–4 weeks. |
| Domperidone / metoclopramide [Rx specialist-directed, NOT gastric acid-reducing] | Not routine GERD PPMAC drugs. GI motility disorders only; dosing individualized by prescriber (not specified in GERD lecture). | QT/arrhythmias with domperidone; EPS/tardive dyskinesia & obstruction with metoclopramide. | Domperidone interactions with QT prolongers/CYP3A4 inhibitors; metoclopramide with antipsychotics/CNS sedatives. | Clinical indication and cardiac/neurological monitoring with prescriber. |
06 | Dyspepsia / epigastric pain
BC MACS: gastric acid-reducing Schedule I medicines ONLY in suitable presentationsLecture basis: GI 11 slides 54–69Risk factors / causes
Female sex; H. pylori infection; NSAIDs, ASA, steroids, iron, bisphosphonates, metformin, antibiotics, KCl; smoking, alcohol, caffeine, spicy/acidic foods. Differential includes ulcer, GERD, gastroparesis, biliary disease, celiac, malignancy, angina.
Clinical presentation
Epigastric pain/burning, postprandial fullness or early satiety, sometimes nausea/belching/bloating. Functional dyspepsia is diagnosis after exclusion of structural disease (Rome pattern ≥3 months, started ≥6 months ago). Unlike GERD, heartburn/regurgitation is not predominant.
When to REFER / exclude self-care
Same alarm features as GERD: GI bleeding, anemia, weight loss, persistent vomiting, dysphagia, mass, family cancer history, suspected cardiac pain; onset >50 new/worsening, younger with high risk; unexplained persistent dyspepsia needing H. pylori testing/endoscopy; incomplete response at 2–4 weeks.
Complications + goals
Complications: Peptic ulcer complications if missed (bleeding/perforation), malnutrition/quality of life; misdiagnosed cancer or ischemia.
Goals: Reduce epigastric symptoms/fullness; treat H. pylori when identified, avoid offending medicines, minimize long-term acid suppression.
| Drug / strength / status | Dose · frequency · duration | Contraindications / precautions | Adverse effects / interactions | What to monitor |
|---|---|---|---|---|
| PPI [MACS Rx] | usual once-daily options | Omeprazole 20 mg; esomeprazole 20–40 mg; lansoprazole 30 mg; pantoprazole 40 mg; rabeprazole 20 mg; dexlansoprazole 30–60 mg PO daily, usually before breakfast (except dexlansoprazole). Trial 4–8 weeks; refer if no response by 2–4 weeks. | All GERD alarm features. Assess H. pylori test need before empiric PPI as PPI can affect test results; prolonged use should be justified. | Headache, diarrhea/constipation, rare AIN; omeprazole/esomeprazole–clopidogrel interaction; absorption of pH-dependent drugs. | Record pain/fullness 0–10, intake and response at 2–4 weeks; taper/stop if resolved. |
| Famotidine [OTC/Rx] | 10/20/40 mg | 10–20 mg PO up to BID (OTC) or prescribed 20–40 mg BID; lecture second-line option x 4–8 weeks. | Renal impairment, alarm signs; less effective than PPI. | Headache, dizziness, GI symptoms; reduced absorption of pH-dependent drugs; tachyphylaxis. | Symptom relief and frequency, renal function if needed. |
| Antacids/alginate [OTC] | Per formulation PRN; useful for short-term symptom relief when reflux overlaps; not proven functional dyspepsia treatment. | Renal impairment with Al/Mg, hypercalcemia with high-dose Ca, drug chelation. | Diarrhea/constipation, chelation DDIs; separate medications. | Prompt symptom relief only; reassess ongoing need. |
| TCAs (amitriptyline/imipramine) or prokinetics [clinician-directed Rx, NOT MACS for dyspepsia] | Discussed for refractory functional dyspepsia after PPI; lecture does not specify dose. Requires physician-led diagnostic plan. | TCA cardiac/anticholinergic risk; prokinetic EPS/QT and obstruction risks. | Dry mouth, constipation, sedation, cardiac effects; many CNS and QT interactions. | Specialist assessment for refractory symptoms and monitoring. |
07 | Constipation: acute, chronic, opioid-induced
OTC management; newer laxatives and PAMORAs are clinician-prescribed, NOT a constipation MACS indicationLecture basis: GI 05 slides 8–53Risk factors / causes
Female sex, pregnancy, older age, low fluid/fibre, immobility, changing routine. Drugs: opioids, anticholinergics, TCAs, antipsychotics, CCBs, diuretics, iron, Ca/Al, ondansetron, loperamide, cholestyramine. Diseases: hypothyroidism, diabetes, CKD, Parkinson, MS, IBS-C, obstruction, pelvic-floor dyssynergia.
Clinical presentation
Hard/lumpy stools (Bristol 1–2), straining, incomplete evacuation, bloating/discomfort and infrequent BMs. Chronic: ≥2 symptoms for >25% of BMs in last ≥3 months, onset ≥6 months before; <3 spontaneous BMs/week may be one criterion. OIC: new/worse symptoms after starting/escalating opioid; tolerance to constipation seldom develops.
When to REFER / exclude self-care
SEVERE abdominal pain/distention, vomiting, no flatus (possible obstruction); blood/black stools, rectal mass/tenesmus, fever, anemia, weight loss, family IBD/CRC, abrupt change, new onset ≥50; >2 weeks persistent constipation or no BM >7 d despite laxatives; in infants: neonatal onset, failure to thrive, severe distention, fever/blood. Do not give bulk or stimulants with suspected obstruction.
Complications + goals
Complications: Hemorrhoids, anal fissure, impaction/overflow incontinence, prolapse, stercoral ulcer, ileus/intestinal obstruction.
Goals: Soft non-forced comfortable BM at individualized frequency, usually ≥3/week; acute relief within 1–3 d; prevent complications and use lowest necessary laxatives.
| Drug / strength / status | Dose · frequency · duration | Contraindications / precautions | Adverse effects / interactions | What to monitor |
|---|---|---|---|---|
| Psyllium (Metamucil) [OTC] | sachets; typical 3.4 g/dose | 3.4–6.8 g PO once daily up to TID; maximum ~30 g/day per lecture. Full glass ≥250 mL every dose. Titrate weekly. Onset 12–72 h. | Dysphagia, esophageal stricture, impaction, obstruction, dehydration/fluid restriction, pelvic floor dyssynergia. | Bloating/gas; may delay other drug absorption (physical trapping): space ~2 h from other oral drugs. | Stool softness and bloating at 3–7 d, BM pattern at 2–4 weeks. |
| Methylcellulose (Citrucel) / calcium polycarbophil [OTC] | Methylcellulose 2 caplets once daily to QID (strength label-dependent); polycarbophil 2 ×625-mg caplets once daily to QID, max 8/day; onset 12–72 h. | Same swallowing/obstruction/fluid restrictions as bulk fibre. | Bloating; separate other oral drugs by ~2 h. | Hydration and stool consistency over days–weeks. |
| Inulin fibre gummies [OTC] | 4 g PO BID per lecture; confirm actual product strength and maximum. | Not with obstruction or inadequate fluid; high FODMAP sensitivity. | Gas/bloating; few systemic DDIs. | Tolerance after 1 week. |
| Polyethylene glycol PEG 3350 [OTC] | 17-g sachet/cap | 17–34 g PO dissolved in ~250 mL fluid once daily; titrate to effect. Onset 48–96 h. Can maintain for chronic constipation when appropriate. | Suspected bowel obstruction; severe unexplained abdominal pain; dehydration requiring other care. | Diarrhea, cramping, bloating; few drug interactions in routine doses; lecture suggests 2-h separation in osmotic group—more relevant for some drugs/rapid GI transit than direct binding. | Stool form/BMs by days 3–5, fluid intake; excessive diarrhea/electrolyte symptoms with overuse. |
| Lactulose [OTC/Rx depending formulation] | commonly 667 mg/mL syrup | 15–30 mL PO once daily to TID; lecture max 90 mL/day. Onset 24–48 h. Sweet syrup can dilute. | Bowel obstruction; galactose restriction/galactosemia (specific product); diabetes usually acceptable but consider sugars. | Flatus, bloating, cramps, diarrhea; may impair absorption when GI transit accelerated, separate ~2 h per lecture. | BM response days 2–3; bloating/electrolytes if chronic diarrhea. |
| Glycerin suppository [OTC] | adult 2.6 g | Insert 1 suppository PR once daily to BID or PRN; moisten, retain ~15 min. Onset 15–60 min. Use for short rescue. | Rectal fissure, fistula, severe hemorrhoids/proctitis, obstruction. | Rectal irritation/burning; no substantial systemic DDIs. | Passage within 1 h; rectal bleeding/pain. |
| Magnesium hydroxide (Milk of Magnesia) [OTC] | common 400 mg/5 mL | 2.4–4.8 g PO at bedtime or divided (e.g. 30–60 mL using 400 mg/5 mL); acute short-course only. Onset 0.5–6 h. | CKD/renal failure, heart disease, severe dehydration, bowel obstruction; frail elders. | Cramps, diarrhea, hypermagnesemia and fluid/electrolyte disorder; chelates quinolones, tetracyclines, iron, levothyroxine, digoxin. | BM within hours, weakness/confusion/bradycardia in renal risk. |
| Sodium phosphate enema [OTC] | typical adult ~120 mL | One adult rectal enema (~120 mL; 26.4 g phosphate per lecture), 2–15 min onset. DO NOT repeat routinely or use without label check. | Renal impairment, dehydration, HF, elderly frailty, obstruction; children require specific guidance. | Severe phosphate/calcium and renal abnormalities, rectal burning; interacting nephrotoxins. | Stool within 15 min; urgent assessment if severe pain or no response. |
| Bisacodyl [OTC] | 5-mg enteric tabs, 10-mg suppository | PO 5–10 mg at bedtime PRN, onset 6–12 h; PR 10 mg once daily PRN, onset 15–60 min. Short rescue/occasional use. | Bowel obstruction, acute surgical abdomen, severe dehydration; enteric coating—do not crush. | Cramps, diarrhea, hypokalemia if overused. Separate ENTERIC-COATED oral form 1–2 h from milk, antacids, H2RA or PPI (early dissolution); caution diuretics/digoxin if electrolyte loss. | BM next morning or in 1 h rectally; stool/abdominal cramps, electrolytes if repeated. |
| Sennosides / senna [OTC] | 8.6-mg tablet | 2–4 tabs PO at bedtime; lecture maximum 4 tabs BID (68.8 mg/day). Onset 6–12 h. Titrate to minimum. | Obstruction, severe dehydration, acute unexplained abdominal pain. | Cramps, diarrhea, urinary/stool discoloration; hypokalemia with prolonged excessive use → digoxin/diuretic concern. | Next-day BM, cramping; avoid chronic uncontrolled use. |
| Docusate sodium [OTC] | 100-mg capsule | 100 mg PO BID; onset 12–72 h. Evidence weak; not preferred to treat established chronic constipation. | Obstruction, nausea/vomiting with acute abdominal pain; concomitant mineral oil. | Mild nausea/cramps; facilitates absorption of mineral oil, increasing toxicity. | Stool softening/straining at 2–3 d; switch if ineffective. |
| Mineral oil [OTC] | PO solution / rectal enema | Rectal 60–150 mL PR as occasional rescue (~2–15 min); oral 15–45 mL at bedtime sitting upright (~6–8 h); only short term <1 week if alternatives unsuitable. | Avoid PO with dysphagia, frailty, children, bedridden or aspiration risk; obstruction. | Lipoid pneumonia if aspirated, seepage; malabsorption fat-soluble vitamins and oral contraception; avoid with docusate. | Respiratory symptoms after aspiration, leakage; avoid long-term use. |
| Linaclotide [Rx; NOT MACS] | 145-microgram capsule | 145 micrograms PO once daily ≥30 min before first meal; assess response ~1–4 weeks, trial ~8 weeks if prescribed. | Known/suspected bowel obstruction; avoid children, particularly <6 y; indication-specific adult dose. | Diarrhea, abdominal pain, headache; low systemic DDIs. | BM frequency, severe diarrhea/dehydration after start. |
| Plecanatide [Rx; NOT MACS] | 3-mg tablet | 3 mg PO daily with/without food, adult; onset ~1 day to 1 week; evaluate after several weeks. | GI obstruction; avoid young children; adult indication. | Diarrhea/dehydration; minimal systemic interactions. | Diarrhea and spontaneous BMs first week. |
| Prucalopride [Rx; NOT MACS] | 1/2-mg tablet | 2 mg PO daily (often 1 mg in older/frail or severe renal impairment; lecture 1–2 mg >65); discontinue if ineffective by 4 weeks. | GI perforation/obstruction, dialysis/severe renal impairment depending product, IBD severe active disease. | Headache, nausea, diarrhea; possible interactions noted with ketoconazole, erythromycin, digoxin; renal dosing. | BM within days–4 weeks, headache/GI tolerance; refer for serious mood change. |
| Naloxegol / methylnaltrexone [Rx; NOT MACS] | product-specific | PAMORAs for refractory OIC after appropriate laxative regimen, not routine OTC; exact product doses/strengths not supplied in lecture—verify monographs. | Known/suspected GI obstruction, risk of perforation; opioid antagonist combinations. | Abdominal pain, diarrhea, rare withdrawal; naloxegol strong CYP3A4 interacting drugs. | BM response in days; withdrawal symptoms and abdominal pain. |
08 | Acute diarrhea and travellers’ diarrhea
OTC self-care only; antibiotic treatment requires appropriate prescriber (not a diarrhea MACS indication)Lecture basis: GI 04 slides 3–27Risk factors / causes
Infectious fecal-oral exposure (food/water, daycare, travel, contacts); medications: antibiotics, metformin, Mg, colchicine, PPIs, SSRIs, thyroid hormone, caffeine, laxatives; lactose/other intolerance. Travel risk: contaminated food/water, ETEC/EAEC, Campylobacter, Shigella, Salmonella, Giardia, norovirus.
Clinical presentation
≥3 loose stools/24 h, fluidity/frequency increase. Acute <14 d, persistent 14–30 d, chronic >30 d. Mild TD: tolerable; moderate: interrupts activity; severe: incapacitating or ANY dysentery. Assess stool blood/mucus, fever, abdominal pain, recent antibiotics and dehydration.
When to REFER / exclude self-care
Same-day evaluation: blood/melena/mucus, fever >38.5 °C (or >38 °C in infant <3 mo), marked pain/cramps, severe dehydration, ongoing vomiting >4 h, weight loss, recent antibiotic use/C. difficile concern, toxic appearance, prolonged course or failure to improve after 48 h; urgency increased in infants/frail/immunocompromised.
Complications + goals
Complications: Hypovolemia, AKI, electrolyte imbalance, hypoglycemia in infants, malnutrition; invasive bacterial disease/hemolytic uremic syndrome depending pathogen.
Goals: Replace fluid/electrolytes and maintain intake; reduce troublesome stools while not masking invasive infection; prevent transmission.
| Drug / strength / status | Dose · frequency · duration | Contraindications / precautions | Adverse effects / interactions | What to monitor |
|---|---|---|---|---|
| Oral rehydration solution (Pedialyte/Hydralyte) [OTC] | prepared product | Use correctly mixed commercial ORS; adults sip often and replace ongoing stool losses; children use weight/age-appropriate dosing per clinical guidance. No one universal volume provided by slide. | Unable to tolerate fluids, shock/ileus, severe dehydration → emergency IV fluid assessment. | Usually safe; inappropriate mixing may disturb sodium. | Urine output, dizziness, thirst, weight, tears/wet diapers; assess after each illness day. |
| Psyllium [OTC] | typical 3.4-g dose | For nonspecific mild diarrhea, may use soluble fibre with sufficient water per product; no self-treatment >48 h. Pregnancy-preferred symptomatic option per lecture. | Dysphagia, obstructive disease, inadequate hydration; not a substitute for ORS. | Bloating, impaired oral-med absorption; separate ~2 h. | Stool form at 24–48 h and hydration. |
| Bismuth subsalicylate (Pepto-Bismol) [OTC] | 262-mg chewable | For acute diarrhea or TD: 524 mg PO q30–60 min PRN, max 8 doses/24 h (16 ×262-mg tablets); generally ≤2 d for illness. TD prevention in adults: 524 mg BID (low), QID (standard), or 1,048 mg QID (high) for no more than 3 weeks—NOT routine recommendation. | Salicylate allergy, active bleeding/ulcer, anticoagulant use, pregnancy, <12 y and avoid in <18 with viral illness; renal disease. | Black stool/tongue, tinnitus with high use, nausea/bleeding; ASA/NSAIDs, warfarin/DOACs and tetracycline interaction. | Reduced stools in 24–48 h, hydration, salicylate toxicity. |
| Loperamide (Imodium) [OTC] | 2-mg capsule/tablet | 4 mg PO initially then 2 mg after each loose stool, max 16 mg/day per lecture; check the exact Canadian OTC package maximum. ONLY short-term ≤48 h. | Bloody diarrhea/dysentery, high fever, C. difficile, suspected invasive infection, ileus, severe colitis; <2 years contraindicated. | Constipation, cramps, ileus; serious arrhythmias at overdose or with interacting P-gp/CYP3A4/2C8 inhibitors; avoid supra-label doses. | Stool count within hours; distention, fever, dehydration, no improvement at 48 h. |
| Diphenoxylate 2.5 mg / atropine 0.025 mg tablet (Lomotil) [Rx; NOT MACS] | Lecture: 2 tabs PO QID, OR 2 tabs once then 1 tab after each loose BM; max diphenoxylate 20 mg/day. Brief ≤48-h relief if appropriately prescribed. | Invasive infection, bloody diarrhea, severe hepatic disease, children (lecture avoid <6 and generally all pediatrics), pregnancy/breastfeeding. | Sedation, dry mouth, urinary retention, constipation, ileus; opioids/alcohol/sedatives additive CNS depression. | Bowel frequency, sedation and anticholinergic toxicity; refer worsening. |
| Azithromycin [clinician-directed Rx, NOT MACS] | 250/500-mg tabs | TD: 1,000 mg PO once OR 500 mg PO daily x 3 d; single dose may be split for tolerability. Preferred for febrile diarrhea/dysentery and some fluoroquinolone-resistant regions; individualized by prescriber. | Macrolide allergy; QT prolongation/arrhythmia risk, liver disease. | Nausea/diarrhea, QT; QT-prolonging drugs (e.g. some antipsychotics/antiarrhythmics), warfarin may need INR monitoring. | Clinical improvement in 24–48 h, fever/blood, GI tolerance. |
| Ciprofloxacin [clinician Rx] | 500-mg tab | TD: 500–1,000 mg once OR 500 mg BID x 3 d; resistance and safety concerns may make it unsuitable. | Pregnancy/pediatric restrictions, tendon disorder, myasthenia gravis, QT risk, aortic aneurysm risk, serious prior fluoroquinolone reaction. | Tendon rupture, neuropathy, CNS effects, dysglycemia, C. difficile; chelation with antacids/iron; tizanidine CONTRAINDICATED, warfarin interaction. | Symptom improvement ≤48 h; emergent tendon/neurologic effects. |
| Levofloxacin / norfloxacin [clinician Rx] | 500 mg / 400 mg | TD lecture: levo 500 mg once or daily x 3 d; norfloxacin 800 mg once or 400 mg BID x 3 d. Availability/resistance must be checked; avoid routine prophylaxis. | Similar fluoroquinolone major cautions; renal dose adjustments. | Tendinopathy, neuropathy, QT, C. difficile; chelation with minerals. | Symptoms after 24–48 h, antibiotic AEs. |
| Rifaximin [clinician Rx] | 550 mg marketed in Canada | Lecture treatment: 200 mg PO TID x 3 d, BUT 200-mg tablets unavailable in Canada per slide; this regimen cannot simply be dispensed using 550-mg tablets. Only for NONINVASIVE diarrhea; obtain prescriber advice. | Fever, blood/dysentery, suspected invasive Campylobacter/Salmonella/Shigella; rifamycin hypersensitivity. | Nausea/headache; possible interaction with cyclosporine; route/strength mismatch. | Need for reassessment and appropriate available strength. |
| Cefixime [clinician Rx] | 400-mg tablet | TD lecture: 400 mg PO once OR daily x 3 d as last-line when macrolides/FQs contraindicated. Lecture cautions no TD clinical outcome data; NOT routine choice. | Serious beta-lactam allergy, severe renal dysfunction dose adjustment. | Diarrhea, rash, C. difficile; warfarin may increase INR. | Clinical response 24–48 h. |
| Dukoral oral cholera vaccine [travel clinic] | Not recommended routinely to prevent TD. Lecture schedule if otherwise indicated for cholera: 2 doses, ≥1 week apart, complete ≥1 week before travel; >6-week interval restart; verify destination/age requirements. | <2 y, pregnancy not routinely recommended in lecture; vaccine-specific allergies; risk-benefit individualization. | GI discomfort; no treatment role in ongoing diarrhea. | Do not interpret as reliable TD protection; food/water precautions still essential. |
09 | Nausea/vomiting: cause-first triage, motion sickness, PONV
OTC symptomatic care; most antiemetic Rx indications listed here are NOT BC MACSLecture basis: GI 07 slides 5–61Risk factors / causes
Motion: age 3–12, female sex, migraine, anxiety, hormonal shifts, poor ventilation. General: gastroenteritis, pregnancy, opioids, metformin, antibiotics, digoxin, chemotherapy, surgery, CNS disease, DKA/uremia, obstruction or pancreatitis. PONV: female, nonsmoker, age <50, past PONV/motion sickness, volatile general anesthesia, postoperative opioids.
Clinical presentation
Nausea, retching, emesis +/- pallor, sweating, salivation, dizziness. Motion = travel/visual–vestibular mismatch. Opioid onset often soon after start/escalation. PONV generally first 24 h after surgery. GI infection may coexist with diarrhea/fever; check vomitus for blood/bile and volume.
When to REFER / exclude self-care
Immediate evaluation for blood/coffee-ground or bilious emesis, severe abdominal pain/fever, confusion, head injury, dehydration, major weight loss, persistent >3 d unexplained, child vomiting >6 h per slide, no urine/significant lethargy, pregnancy with poor intake, suspected DKA/obstruction/cardiac event; infants require lower threshold.
Complications + goals
Complications: Dehydration/hypovolemia, hypo-/hypernatremia or hypokalemia, AKI, aspiration, tears (Mallory–Weiss), undernutrition, poor adherence; PONV may disrupt wound closure.
Goals: Stop or reduce emesis, maintain oral hydration/med absorption, identify underlying cause, avoid treatment AEs, prevent recurrence.
| Drug / strength / status | Dose · frequency · duration | Contraindications / precautions | Adverse effects / interactions | What to monitor |
|---|---|---|---|---|
| Dimenhydrinate (Gravol) [OTC] | 50-mg tabs, liquid/supps | ADULT oral: 50–100 mg q4 h PRN (max 400 mg/24 h per Health Canada standard); dose ≥30 min, ideally 1–2 h, before travel. 2–6 y: 12.5–25 mg q6–8h, max 75 mg/d; 6–12 y: 25–50 mg q6–8h, max 150 mg/d; under 2 clinician. Short period only. | Narrow-angle glaucoma, urinary retention/BPH, frailty/delirium, severe respiratory disease, hypersensitivity. | Drowsiness, dry mouth, blurred vision, constipation; paradoxical agitation in children; additive alcohol, opioids, benzodiazepines, other antihistamines/anticholinergics. | Sedation/driving and relief within first few hours; adequate intake. Pediatric trial at home before travel per lecture. |
| Diphenhydramine [OTC] | 25/50 mg tablets | ADULT common anti-motion dose 25–50 mg PO 30–60 min before travel and q4–6 h PRN; maximum per product label; not preferred to dimenhydrinate. | Same anticholinergic cautions; children may have paradoxical excitement. | Greater sedation/dry mouth, drug interactions with CNS depressants/anticholinergics. | Response and sedation at travel start. |
| Promethazine [Rx depending formulation] | 25-mg tablet | Adult motion sickness 25 mg PO 1–2 h before travel; repeat per prescriber if needed. Lecture does not give exact repeat schedule. | Children under 2 (respiratory depression), sedatives, respiratory disease, narrow-angle glaucoma, elderly frailty. | Marked sedation, anticholinergic effects, hypotension; opioids/benzodiazepines/alcohol additive; QT risk. | Sedation/respirations and travel response. |
| Meclizine [not commercially available in Canada per lecture] | 25/50 mg historical | Not a readily marketed Canadian OTC option. Motion sickness adult 25–50 mg once before travel in other jurisdictions; Canadian compounding only if appropriately prescribed. | As antihistamine; availability limits. | Sedation/dry mouth; additive CNS depression. | Do not counsel as freely available BC retail stock. |
| Scopolamine transdermal (Transderm-V) [discontinued in Canada] | historical 1.5-mg patch | Historical slide: apply behind ear 4–12 h before travel; remove after 72 h, wash hands. NOT a currently marketed Canadian patch. | Avoid in children and pregnancy per lecture; narrow-angle glaucoma, urinary retention, elders/cognitive impairment. | Dry mouth, blurred vision, confusion; additive anticholinergic effects. | Not a standard retail recommendation; check alternatives. |
| Ginger / P6 acupressure [non-drug / NHP] | P6 massage ≥5 min q4 h per lecture. Ginger for PONV study 1 g PO 1 h before induction under anesthesia oversight; motion sickness dose evidence variable. | Ginger supplements caution when taking anticoagulants or before surgery; allergy. | Heartburn/GI upset possible; potential bleeding interactions at high supplemental doses. | Patient-reported nausea relief; not alternative to hydration. |
| Ondansetron [Rx; NOT nausea MACS] | 4/8-mg oral forms; IV | PONV prophylaxis 4–8 mg IV near end of surgery per lecture. Outpatient oral regimens indication-specific and NOT supplied by lecture—verify prescribing protocol. | Congenital long-QT, other QT drugs, severe hepatic impairment (dose cap); apomorphine combination contraindicated. | Constipation/headache, QT prolongation; serotonergic drugs may rarely cause serotonin syndrome. | ECG/electrolytes if QT risks, nausea and bowel function. |
| Palonosetron [hospital Rx] | IV 0.075 mg | PONV prevention 0.075 mg IV at anesthesia induction per lecture. | Known allergy, caution QT predisposition. | Headache, constipation; serotonergic co-medication caution. | Hospital PONV response in first 24 h. |
| Droperidol [hospital Rx] | IV 0.625–1.25 mg | PONV prophylaxis 0.625–1.25 mg IV near end of surgery per lecture. | QT prolongation, electrolyte abnormalities, Parkinson disease, CNS depression. | QT/TdP, hypotension, EPS; additive QT agents and sedatives. | ECG/electrolytes per local anesthesia protocol; EPS. |
| Haloperidol [hospital Rx] | 0.5–2 mg IM/IV | PONV prophylaxis 0.5–2 mg IM/IV per lecture, specialist-administered. | Parkinson disease/Lewy-body dementia, prolonged QT, severe CNS depression. | EPS/akathisia, QT, sedation; antipsychotics/QT and CYP-interacting agents. | QT and movement disorder observations perioperatively. |
| Aprepitant [hospital Rx] | 40/80-mg capsule | PONV prevention 40–80 mg PO near induction per slide; clinical regimen protocol-specific. | CYP3A4 interacting drugs; assess contraception interaction. | Fatigue, headache, hiccups; reduces hormonal contraceptive effectiveness, increases exposure to some CYP3A4 substrates (e.g., dexamethasone). | Vomiting first 24 h, interaction reconciliation. |
| Dexamethasone / methylprednisolone [hospital Rx] | PONV prevention: dexamethasone 4–8 mg IV at induction; methylprednisolone 40 mg IV at induction per lecture. | Infection concerns, hypersensitivity; caution diabetes/hyperglycemia, active ulcer. | Transient hyperglycemia, insomnia, GI upset; NSAIDs may increase GI ulcer risk. | Perioperative glucose (diabetes), infection risk. |
| Perphenazine / metoclopramide [hospital or clinician Rx] | PONV slide: perphenazine 5 mg IM/IV; metoclopramide 25–50 mg IV perioperatively; these are HIGH/specialist protocols, NOT retail dosing. Other nausea regimens require monograph check. | Metoclopramide: obstruction/perforation/bleeding, epilepsy, Parkinson, tardive dyskinesia history. Perphenazine: QT/EPS risks. | Akathisia, dystonia, tardive dyskinesia, sedation; antipsychotics/other EPS agents and QT drugs add risk. | Neurological effects, agitation, QT when indicated. Do not extrapolate these doses to outpatient patients. |
| Domperidone [Rx; NOT MACS] | 10-mg tabs | No N/V dose specified in lecture; use only per authorized prescriber/monograph, not for generic OTC nausea. | Known prolonged QT, heart disease, electrolyte disturbance, strong CYP3A4 inhibitors and QT drugs. | QT/arrhythmia, prolactin effects; macrolides/azole antifungals high-risk co-prescription. | ECG/electrolytes if appropriate, symptom response and shortest use. |
10 | Topical OTC analgesics and localized MSK pain
BC MACS: musculoskeletal pain — Schedule I NSAIDs only; topical OTC options are recommended (not prescribed)Lecture basis: MSK 07 slides 8–45Risk factors / causes
Overuse, strain/sprain, osteoarthritis (superficial joints), repetitive work/sport, trauma. Check age; pregnancy, CKD, CVD, peptic ulcer/bleeding, anticoagulants, aspirin-sensitive asthma; exposure to other oral or topical NSAIDs; skin condition and location.
Clinical presentation / complications
Localized movement-related pain/tenderness; acute sprain may have swelling/bruising and limited ROM; OA mechanical pain/stiffness. Consider neuropathic pain, radiculopathy and inflammatory or infectious disease. Complications: impaired mobility, chronic pain; burns or salicylate toxicity from misuse.
Refer / do not self-treat
Immediate: deformity, neurovascular loss, severe trauma, inability to bear weight (Ottawa ankle/foot rules when applicable), hot swollen joint with fever, chest/back vascular red flags. Urgent/routine: persistent >7–14 d, enlarging swelling, neurological weakness, unexplained weight loss, nocturnal unrelenting pain, large-area application requested.
Goals / treatment selection
Reduce pain, improve movement/function, reduce use of systemic medications and avoid adverse reactions. For acute peripheral MSK pain a topical NSAID has stronger evidence than counterirritants; deeper hip/back lesions respond less reliably.
| Drug / category / scope | Strength • dose • duration / application | Contraindications / avoid / precautions | Interactions / key adverse effects | Effectiveness + safety monitoring |
|---|---|---|---|---|
| Diclofenac diethylamine 1.16% gel (OTC; topical NSAID) | Thin layer over affected joint/soft tissue three to four times daily; 2 cm strip ≈1 g covers ~200 cm² in lecture example. Typical acute sprain trial up to 7 days; label may permit 7–14 days depending on indication. | NSAID hypersensitivity/aspirin-exacerbated respiratory disease; avoid in third trimester, on wounds, with severe renal/GI/CV risk or large-area prolonged use. Confirm age and product label. | Irritant dermatitis, dryness; systemic GI/renal/CV effects possible with high-dose/area; avoid combining with oral NSAIDs if possible, watch ACEi/ARB + diuretic + NSAID and anticoagulants. | Pain/function after 3–7 days; rash or wheeze immediately; review if ineffective after 7 days. |
| Diclofenac diethylamine 2.32% gel (OTC; extra strength) | Apply ~2 g (4 cm strip) twice daily to affected area; lecture example max 4 g/day for product. Confirm actual pack insert/site and age. | Same NSAID contraindications as 1.16%; not for mucosa/eyes; avoid occlusion and external heat. | Skin irritation; low but not absent systemic exposure; higher risk with concomitant oral NSAIDs, warfarin, nephrotoxic drugs. | Pain and mobility at days 3–7; safety review with persistent application beyond label period. |
| Capsaicin 0.025% / 0.075% cream (OTC; capsaicinoid) | Small amount to intact skin 3–4 times daily; effect requires consistent use for ~2–4 weeks (more established for some neuropathic/OA pain than acute sprain). Wash hands after. | Avoid broken skin, eyes, mucous membranes, heat/bandaging, acute highly inflamed injury; check product/age. | Initial burning, erythema, coughing from aerosolization; avoid additional irritant creams or heat (burn risk). | Tolerance of burning first days; reassess analgesia 2–4 weeks; stop for blistering. |
| Methyl salicylate (≈10–30%) ± menthol/camphor (OTC; counterirritant) | Apply thin film according to label, often up to 3–4 times/day; rub gently. Formulations variable (e.g., Rub A535 methyl salicylate 18% + camphor 1% + menthol 0.75%). | Avoid ASA allergy, bleeding disorders, children with salicylate risk, pregnancy unless cleared, large areas, heat, occlusion or broken skin. | Warfarin: salicylate absorption may increase INR/bleeding; skin burns, irritant/allergic dermatitis, rare systemic salicylate toxicity. | Assess symptom relief after several days; review skin, bruising, tinnitus/nausea/salicylate symptoms if overused. |
| Menthol 2–5% / camphor / eucalyptus oil (OTC; counterirritants) | Use label-specific thin application, usually ≤3–4 times/day; concentrations differ widely by product. No standardized course. | Avoid babies/young children depending on ingredient, sensitive skin, damaged skin, mucosa, occlusive dressings or external heat. | Cooling/burning/irritation; camphor ingestion is toxic, including seizures; keep away from children. Evidence of benefit limited. | Pain/skin tolerance within 3–7 days; stop irritation. |
| Arnica topical preparations (OTC natural product) | Use exact labelled frequency and formulation only; no established evidence-based dosing for sprain benefit. | Plant-family allergy; do not apply on open wounds; avoid oral non-standard arnica toxicity. | Contact dermatitis; limited efficacy and variable natural health product quality. | Trial within a few days, discontinue if ineffective; avoid replacing more effective care. |
11 | Uncomplicated lower urinary tract infection (acute cystitis)
BC MACS: uncomplicated UTI — antibiotic Schedule I drugs; complicated UTI/pyelonephritis excludedLecture basis: IID 16 pp. 2–13 (especially pp. 6–10)Risk factors / causes
Urinary anatomy, sexual activity/new partner, spermicide, previous UTI, menopause/vaginal atrophy, incomplete voiding; recent antibiotic exposure/resistant isolate, diabetes with poor control, immunosuppression, urinary tract abnormalities/catheter and stones increase complicated infection risk. E. coli predominant.
Clinical presentation / complications
Acute dysuria + frequency/urgency ± suprapubic discomfort and cloudy urine, WITHOUT fever, flank pain, vomiting or systemic illness. Distinguish vaginitis/STI (discharge, itch, pelvic pain). Pyelonephritis: fever, chills, flank/CVA pain, nausea/vomiting. Complications: ascending infection, renal scarring rarely, bacteremia/urosepsis.
Refer / do not self-treat
Immediate/urgent: fever/chills, flank pain, sepsis, inability to tolerate fluids, pregnancy, suspected obstruction. Refer for male/prostate symptoms, catheter, urinary anomaly, immunosuppression/poorly controlled diabetes, significant renal impairment, first unclear diagnosis, recurrent/relapsing within 1 month, persistent >2 weeks, suspected STI/vaginitis, age <16, LTC residence, no improvement by 48h. The 2025 lecture flags CrCl <60 mL/min for referral; nitrofurantoin-specific avoidance threshold is <30 mL/min.
Goals / treatment selection
Eradicate infection, resolve pain/frequency promptly, avoid pyelonephritis/sepsis and antimicrobial resistance. For low-risk typical cystitis, choose a short narrow regimen; compare prior cultures and local resistance, recent antibiotics, pregnancy and renal function.
| Drug / category / scope | Strength • dose • duration / application | Contraindications / avoid / precautions | Interactions / key adverse effects | Effectiveness + safety monitoring |
|---|---|---|---|---|
| Nitrofurantoin monohydrate/macrocrystals 100 mg (Macrobid; BC MACS) | 100 mg orally twice daily WITH FOOD for 5 days. Must not use for pyelonephritis; confirm product as BID versus QID form. | Avoid if eGFR/CrCl <30 mL/min (local guidance may be more conservative), history of nitrofurantoin-related liver/lung toxicity; G6PD deficiency, near term pregnancy/neonates: specialist check. | Nausea, headache, brown urine; rare pulmonary/hepatic injury and neuropathy. Antacids with magnesium trisilicate reduce absorption; probenecid reduces renal excretion. | Dysuria/urgency begin improving within 24–48 h; review if persistent at 48 h. Immediate stop/refer for dyspnea, cough, jaundice or neuropathy. |
| Nitrofurantoin macrocrystals 50–100 mg (alternative formulation) | 50–100 mg PO four times daily for 5 days when appropriate and available; differs from modified-release BID product. | Same safety as above; swallowing, dosing burden and adherence must be considered. | More frequent GI complaints; same rare serious toxicities. | Check correct formulation and adherence at 48 h. |
| Fosfomycin tromethamine 3 g granules/sachet (Monurol; BC MACS) | Dissolve 3 g sachet in ~½ cup cold water; take immediately ONCE (single dose), ideally 2–3 h after meal, often at bedtime after voiding. | Avoid for pyelonephritis or invasive infection; consider resistance and prior isolate. Limited data for severe renal impairment. | Diarrhea, headache, nausea; metoclopramide lowers fosfomycin serum/urinary concentrations (avoid combination). | At 48–72 h assess clinical improvement; if persistent, culture/medical review. |
| TMP/SMX DS 160/800 mg (BC MACS when suitable) | One DS tablet PO twice daily x 3 days; only if local E. coli resistance <20% and no resistant history/recent use; tailor to C&S. | Sulfonamide allergy, severe renal/hepatic impairment, pregnancy caution, G6PD deficiency, severe cytopenias. Dose adjust for renal function. | Rash/SJS, nausea, hyperkalemia, creatinine increase; major interactions: warfarin (↑INR), ACEi/ARB/spironolactone (↑K), methotrexate (marrow toxicity), phenytoin. | Symptoms at 48 h; monitor potassium/creatinine in risk patients, INR closely with warfarin; counsel urgent rash or mucosal lesions. |
| Trimethoprim 100 mg (alternative Rx within category) | 100 mg orally twice daily OR 200 mg once daily for 3 days where formulation/availability permits. | Pregnancy/folate deficiency, significant renal impairment, prior resistance; patient-specific check. | Hyperkalemia with RAAS blockers, methotrexate interaction, rash, GI upset. | Symptoms 48 h; potassium/renal function if high risk. |
| Amoxicillin/clavulanate 875/125 mg (alternative Rx) | 875/125 mg PO twice daily for 5–7 days as guided by local resistance, allergy and susceptibility. Not routine first-line. | Immediate penicillin allergy, prior amox-clav cholestatic liver injury, dose considerations for CKD. | Diarrhea, candidiasis, cholestatic hepatitis, C. difficile risk; warfarin may elevate INR. | Symptoms 48 h; diarrheal adverse effects and rash during course. |
| Cephalexin 250–500 mg / cefixime 400 mg (alternative Rx) | Cephalexin 250–500 mg orally four times daily x 5–7 d; OR cefixime 400 mg daily x 5–7 d, if indicated by local guidance and susceptibility. | Severe beta-lactam allergy and renal dose adjustment; avoid indiscriminate broad-spectrum choices. | Diarrhea/rash, candidiasis, C. difficile, possible warfarin-INR alteration. | Symptom improvement by 48 h; adverse effects through treatment. |
| Ciprofloxacin 250 mg (reserved Rx—not routine MACS first choice) | 250 mg PO twice daily x 3 days for uncomplicated cystitis only if safer options inappropriate and justified by susceptibility. Avoid indiscriminate use. | Pregnancy, serious FQ reactions history, QT risk, myasthenia gravis, aortic aneurysm risk; not preferred due to serious harms/resistance. | Tendinopathy/rupture, neuropathy, CNS effects, dysglycemia, QT; chelation by Ca/Fe/Mg/Zn; ↑warfarin INR, tizanidine contraindicated. | Review promptly for tendon, neuropathy, palpitations, CNS symptoms; clinical response 48 h. |
12 | Head lice (pediculosis capitis)
OTC treatment / counselling; not a BC MACS prescribing conditionLecture basis: DERM 04/05 slides 4–33Risk factors / causes
Head-to-head contact, school/daycare household exposure, age 3–12, shared sleeping; lice do not fly/jump, do not imply poor hygiene, and pets do not transmit human head lice.
Clinical presentation / complications
Live mobile 2–4 mm insects near scalp; eggs/nits attached to shafts especially behind ears/nape; scalp itch appears weeks after first infestation; excoriations, cervical adenopathy, impetigo from scratching. A nit alone is NOT diagnostic of active infestation.
Refer / do not self-treat
Extensive scalp infection, fever, lymphadenopathy with pus, eyebrow/lash involvement, child younger than labelled age, pregnancy with uncertain product, treatment failure after two properly used courses, persistent live lice despite adherence, differential eczema/seborrhea.
Goals / treatment selection
Kill live lice, interrupt egg hatch cycle, relieve itch and prevent spread/reinfestation; use wet/dry fine-tooth comb to confirm live lice.
| Drug / category / scope | Strength • dose • duration / application | Contraindications / avoid / precautions | Interactions / key adverse effects | Effectiveness + safety monitoring |
|---|---|---|---|---|
| Permethrin 1% crème rinse (Nix, Kwellada-P; OTC) | On washed, conditioner-free towel-dried hair saturate hair and scalp, leave 10 min, rinse; repeat on day 7–10 if instructed/live lice present (consider routine repeat based on regional guidance). Age ≥2 months per lecture; confirm product. | Chrysanthemum/pyrethroid allergy precaution; avoid eyes; irritation not necessarily failure. Resistance is possible. | Transient pruritus, burning, redness, tingling; no important systemic DDIs with correct topical use. | Fine-comb for live lice after treatment and day 7–10; treatment failure means live crawling lice after correctly administered series, not just nits. |
| Pyrethrins 0.33% + piperonyl butoxide 3% shampoo (R&C; OTC) | Saturate dry scalp/hair, leave 10 min; add water and lather then rinse; REPEAT at day 7. Verify label and age ≥2 months. | Avoid chrysanthemum/ragweed/pyrethrin allergy; eye and ignition caution; resistance possible. | Local pruritus, dermatitis/eye irritation; negligible routine DDIs. | Check live lice after 7–10 d and following repeat treatment. |
| Dimethicone/dimeticone-based OTC products (concentration brand-specific) | Physical suffocation/coating products; application on DRY hair and length of contact/repeat interval vary by Canadian manufacturer. Follow exact NPN/DIN label—do not transpose permethrin timing. | Avoid eye contact and flammable heat exposures where formulation indicates. | Temporary skin irritation; minimal systemic interaction potential. | Inspect for live lice at day 7–10; retreat only per product instructions. |
| Mechanical wet combing alone (non-drug alternative) | Work in small sections with fine-toothed comb from scalp to end; repeat every 3–4 days for at least 2 weeks until no lice found. | Feasibility/adherence; can be burdensome with thick/long hair. | Scalp tenderness if vigorous. | Document live lice on each inspection; persistent live lice -> pharmacotherapy/reassessment. |
| Oral ivermectin / alternative off-label agents (prescriber only) | Systemic ivermectin protocols for resistant head lice exist outside routine BC community OTC care; not standard BC head-lice MACS. | Not routinely recommended for pregnancy or children <15 kg; dose based on weight and diagnosis. | Potential CNS/GI adverse effects and DDIs; use prescriber assessment. | After specialist-directed course; live lice, tolerability and reinfection source. |
13 | Scabies (Sarcoptes scabiei)
OTC / clinician-diagnosed; NOT one of BC MACS conditionsLecture basis: DERM 04/05 slides 38–59Risk factors / causes
Prolonged close skin contact, institutional outbreaks, household/sexual contacts, crowded dwellings; immunosuppression and age/frailty increase crusted-scabies risk. Incubation often 2–6 weeks for first exposure, much faster upon reinfestation.
Clinical presentation / complications
Intense generalized itch WORSE AT NIGHT; itchy papules and thin burrows on finger webs, flexor wrists, axillae, beltline, buttocks, genitals; infants may have palms/soles/scalp. Complications: impetigo, post-streptococcal sequelae, crusted hyperinfestation; post-scabetic itching can last 2–4+ weeks despite cure.
Refer / do not self-treat
Confirm diagnosis or refer when atypical, newborn/infant, pregnancy uncertainty, extensive crusting or immune suppression, severe bacterial superinfection, treatment failure, large outbreaks. Urgent assessment with sepsis, rapidly worsening skin disease. Avoid treating a pruritic eruption as scabies without reasonable clinical confidence.
Goals / treatment selection
Eliminate mites and household transmission; treat ALL close/household/sexual contacts at SAME TIME even if asymptomatic; counsel expected persistent itch.
| Drug / category / scope | Strength • dose • duration / application | Contraindications / avoid / precautions | Interactions / key adverse effects | Effectiveness + safety monitoring |
|---|---|---|---|---|
| Permethrin 5% cream (Nix Dermal Cream, Kwellada-P; Schedule II) | Apply fully to clean dry skin from neck to soles including finger webs, under nails, navel and genitals; head/scalp also in infants/elderly or involved areas; leave 8–14 h then wash off. Repeat in 7 days (or 7–10 d) for typical infestation. | Age <2 months requires clinician-directed choice; avoid pyrethroid allergy. Coverage failure is common. Safe choice commonly used in pregnancy and breastfeeding with individual assessment. | Temporary itching, stinging, erythema or eczema; no routine systemic DDIs. | Check new burrows/live mites after 1–2 weeks; do not mistake up to 4 weeks of residual itch for failure. |
| Crotamiton 10% cream/lotion (alternative; verify Canadian availability) | Manufacturer/care protocol dependent, e.g. once daily for 2 successive days and repeat if necessary; less effective than permethrin. | Not preferred in infants/pregnancy without clinician review; avoid face/mucosa. | Irritation, contact dermatitis; low systemic DDI potential. | Persistent new lesions after 1–2 weeks requires referral. |
| Precipitated sulfur 5–10% ointment (compounded; prescriber-supervised) | Apply over body nightly for 3 consecutive nights (protocols vary); often considered in very young infants when needed. | Messy/odorous; formulation and age-specific use require review. | Irritation, dry skin; negligible DDIs. | New lesions after course; refer if persistent. |
| Oral ivermectin (physician-directed, off-label for scabies in Canada) | Typical specialist regimen 200 micrograms/kg orally, repeat after 7–14 days; in crusted scabies additional doses plus topical therapy. NOT BC MACS prescribing. | Avoid routine use in pregnancy, lactation/newborn situations and children <15 kg without specialist oversight; interactions and neurologic disease require review. | Dizziness, GI upset, pruritic flare; interactions with warfarin and other agents need evaluation. | Specialist surveillance 1–4 weeks, confirm household/outbreak treatment and absence of new burrows. |
| Post-scabetic itch: moisturizers ± hydrocortisone 0.5–1% (OTC) | Thin topical low-potency steroid once or twice daily for a brief course (e.g. 5–7 d) to symptomatic areas after mites treated; emollients regularly. | Do not mistake untreated persistent infection or bacterial infection for post-scabetic eczema; avoid long-term steroids on face/folds. | Skin atrophy with prolonged steroid use; minor local irritation. | Itch can linger 2–4 weeks; assess new lesions rather than itch alone. |
14 | Rosacea — phenotype-directed treatment
Counselling / physician or NP prescription (rosacea itself is not BC MACS)Lecture basis: DERM 09 slides 5–49 (file title includes acne but contents primarily rosacea)Risk factors / causes
Adult onset often 30–50; family tendency, fair skin (all phototypes affected), UV, heat, exercise, spicy foods, alcohol, hot beverages, stress, topical steroids, irritating scrubs/astringents, vascular reactivity; Demodex may contribute.
Clinical presentation / complications
Persistent central-face erythema/flushing ± telangiectasia, papules/pustules WITHOUT comedones; burning/stinging, sensitive dry skin; ocular gritty/red eyes; phymatous skin changes. Distinguish acne (comedones), perioral dermatitis, seborrheic dermatitis, lupus. Complications: ocular keratitis/vision risk, rhinophyma, psychological effects.
Refer / do not self-treat
Same-day for eye pain, photophobia, vision change; referral for uncertain diagnosis, severe/rapid progression, rhinophyma, steroid-induced flare, significant ocular disease or failure of 8–12 weeks of appropriate care. Rosacea is not independently prescribable as BC minor ailment.
Goals / treatment selection
Reduce inflammatory lesions and bothersome erythema, prevent triggers/ocular complications; therapy must target phenotype. Brimonidine helps erythema; anti-inflammatory creams target papules/pustules, neither fixes fixed telangiectasia.
| Drug / category / scope | Strength • dose • duration / application | Contraindications / avoid / precautions | Interactions / key adverse effects | Effectiveness + safety monitoring |
|---|---|---|---|---|
| Brimonidine 0.33% gel (Onreltea; prescription outside MACS) | Thin layer once daily over affected persistent erythema; onset ~30 minutes, peaks ~3 h, lasts ~10–12 h. | Caution with cardiovascular/cerebrovascular disease, orthostatic hypotension, severe depression, alpha-agonist sensitivity; avoid eyes/lips. | Flare/rebound erythema, flushing, pallor, irritation; caution other antihypertensives and MAO inhibitors. | Assess same-day cosmetic response and rebound after use; reassess 2–4 weeks. |
| Metronidazole topical 0.75% gel/cream or 1% cream/gel (prescription) | 0.75% often apply twice daily; 1% generally once daily, depending on DIN/product. Continue 8–12 weeks then maintenance. | Hypersensitivity; do not apply to eyes; safety in pregnancy assessed case-by-case. | Irritation/dryness/burning; systemic DDI minimal, though monitor warfarin if very extensive application. | Inflammatory lesion count and irritation at 3–6 weeks, decision at 8–12 weeks. |
| Azelaic acid 15% gel (Finacea; prescription) | Thin layer once or twice daily per product/clinician (lecture uses once daily); titrate based on tolerability; 8–12 weeks initial. | Hypersensitivity; avoid mucosal use, highly irritated skin. | More burning/stinging/itching than metro; few systemic DDIs. | Tolerance week 1–2, papules at weeks 3–6; reassess 8–12 weeks. |
| Ivermectin 1% cream (Rosiver; prescription) | Thin layer to affected facial regions once daily for up to ~12–16 weeks; reassess response at 12 weeks. | Hypersensitivity; pregnancy/breastfeeding require review; not lice/scabies regimen. | Temporary burning/dry skin; minimal systemic DDIs. | Papule/pustule reduction by weeks 4–8, reassess at 12 weeks. |
| Doxycycline 40 mg modified release or 100 mg (systemic prescriber) | For moderate-to-severe inflammatory lesions: 40 mg modified-release daily where Canadian product available; alternatively 100 mg daily according to prescriber, often 6–12 wk, generally limit antibiotic exposure. | Pregnancy, children <8 y, tetracycline allergy, photosensitivity risk, esophageal disease. | Photosensitivity, esophagitis, GI upset, yeast infection; separate calcium/iron/antacids by ≥2–3 h; warfarin INR interaction. | Inflammatory lesions and skin tolerance at 4–6 weeks; resistance/safety review by 8–12 weeks. |
| Oxymetazoline 1% facial cream (US rosacea product) | US prescription option for fixed erythema; not a routine Canadian rosacea product. Do NOT substitute 0.05% nasal decongestant spray onto face. | Similar vasoconstrictor cautions; Canada availability not established. | Rebound erythema/irritation potential. | Not a standard Canadian counselling recommendation. |
15 | Onychomycosis (fungal nail infection)
BC MACS: fungal nail infections — TOPICAL Schedule I drugs onlyLecture basis: DERM 12 slides 3–39Risk factors / causes
Dermatophytes (Trichophyton rubrum), tinea pedis, older age, male sex, occlusive shoes, sports/pools, repetitive nail trauma, diabetes, peripheral vascular disease, immunocompromise, affected household members. Fingernails may involve yeast.
Clinical presentation / complications
Distal/lateral nail yellow-white discolouration, thickening, crumbling, onycholysis, subungual debris; superficial white patches; proximal nail involvement suggests impaired immunity. Differentials psoriasis, trauma, lichen planus, melanoma. Complications cellulitis/foot ulcer in diabetes, discomfort and recurrence.
Refer / do not self-treat
Refer if proximal disease, >50% nail, matrix/lunula involvement, multiple extensively thickened nails, significant pain, rapid pigment change/melanonychia, immunocompromised/poor circulation/diabetic foot, children, failed appropriate topical treatment or unclear diagnosis. Mycology (KOH/culture/PAS) recommended especially before systemic therapy.
Goals / treatment selection
Mycological cure plus gradual regrowth of normal nail (may take ~9–18 months toenails); prevent recurrence by treating tinea pedis and reducing moisture. Topicals suitable for limited distal disease with matrix spared; oral treatment requires another prescriber.
| Drug / category / scope | Strength • dose • duration / application | Contraindications / avoid / precautions | Interactions / key adverse effects | Effectiveness + safety monitoring |
|---|---|---|---|---|
| Efinaconazole 10% solution (Jublia; TOPICAL BC MACS) | Once daily to entire affected nail, folds, nail bed, undersurface and distal tip for 48 weeks; lecture ~1 drop/nail or ~2 drops great toenail, subject to applicator. | Not suitable for severe matrix disease needing systemic treatment; avoid eye/mucosal exposure, assess child/age indication and pregnancy. | Vesicles, dermatitis, erythema; low systemic interactions. | Photo/document healthy new nail at 12, 24 and 48 weeks; mycological outcomes after full course and additional regrowth. |
| Ciclopirox 8% nail lacquer (Penlac; prescription, TOPICAL category) | Apply nightly once daily to nail and surrounding skin for up to 48 weeks; remove built-up coats about weekly using alcohol per label; trim weekly and debride periodically. | Limited efficacy for severe disease; allergy, severe barrier problems; confirm current marketed Canadian product/DIN. | Local erythema, burning, nail shape changes; no substantial DDIs. | Assess adherence/clear nail at 12–24 wk; consider escalation if no response. |
| Propylene glycol + urea + lactic acid solution (Emtrix; OTC) | Apply once nightly to nail and under free nail edge for months (often 3–6 months or more). Cosmetic/keratolytic support; not equivalent to Rx antifungal cure. | Limited efficacy; avoid open painful periungual tissue. | Transient local stinging, irritation or nail whitening. | Appearance at 12–24 weeks; refer if worsening. |
| Terbinafine 250 mg orally (systemic prescriber only) | 250 mg by mouth daily x 6 weeks fingernails or 12 weeks toenails (for dermatophyte disease after confirmation). NOT onychomycosis MACS prescribing. | Active/chronic liver disease, major liver toxicity history; evaluate renal function; pregnancy and breastfeeding need specialist review. | Hepatotoxicity, dysgeusia/anosmia, rash, GI upset; CYP2D6 inhibition may raise metoprolol, TCAs, certain antidepressants. | Baseline hepatic status/LFTs (and repeat based on risk/symptoms), serious rash, jaundice; nail regrowth takes months. |
| Itraconazole 200 mg capsules (systemic prescriber only) | Continuous: 200 mg/day x 6 wk fingers or 12 wk toes; pulse: 200 mg twice daily for 1 week each month (2 pulses fingers, 3–4 toes) when appropriate. | Heart failure/ventricular dysfunction, hepatic disease, pregnancy, marked interacting drugs; capsules need gastric acidity for absorption. | CYP3A4 strong inhibition: simvastatin/lovastatin, some benzodiazepines/QT drugs contraindicated; edema/hepatotoxicity. PPIs reduce capsule absorption. | Baseline liver/drug interaction review and follow-up 4–6 weeks; monitor edema/HF symptoms and slowly advancing normal nail. |
16 | Atopic dermatitis / eczema
BC MACS: dermatitis — topical Schedule I drugs for suitable mild-to-moderate casesLecture basis: DERM 13 slides 7–65Risk factors / causes
Personal/family atopy (asthma, allergic rhinitis, eczema), filaggrin/skin-barrier dysfunction, early childhood onset, irritant soaps/wool, low humidity, sweating/heat, scratching, colonization with S. aureus.
Clinical presentation / complications
Pruritus is hallmark; xerosis, erythema, scale, excoriations, lichenification. Infant: cheeks/extensors; child: flexural surfaces; adult: hands/flexures/eyelids. On darker skin erythema may appear violaceous/hyperpigmented. Complications: impetiginization, eczema herpeticum, sleep disruption and chronic itch-scratch cycle.
Refer / do not self-treat
Urgent: painful monomorphic punched-out vesicles/fever (eczema herpeticum), widespread infected oozing skin, cellulitis, rapidly spreading rash, eye involvement. Routine: extensive or severe, refractory >1–2 wk of correct regimen, diagnostic doubt, inadequate sleep/QOL, infants or special sites needing advanced therapy.
Goals / treatment selection
Restore barrier, rapidly suppress inflammatory flare, eliminate pruritus, minimize relapse and steroid adverse events; choose steroid potency by age, SITE, severity, duration, not merely % strength.
| Drug / category / scope | Strength • dose • duration / application | Contraindications / avoid / precautions | Interactions / key adverse effects | Effectiveness + safety monitoring |
|---|---|---|---|---|
| Hydrocortisone 0.5–1% cream/ointment (OTC low potency) | Thin layer once or twice daily for 5–7 days on face/folds/infant sites if appropriate; body flares often 7–14 days. Hydrocortisone 2% may be Rx depending on product. | Avoid untreated bacterial/fungal/herpetic lesions; caution periocular eyelid use; do not use under occlusion or on large areas without review. | Burning, folliculitis; prolonged use → atrophy, striae, glaucoma if near eyes, HPA suppression with extensive use; minimal DDIs. | Pruritus improves 2–3 d; signs improve within 5–7 d; review nonresponse or spreading infection. |
| Desonide 0.05% / hydrocortisone valerate 0.2% (low–moderate Rx topical) | Apply thin layer once or twice daily for usually 7–14 days, site/formulation-dependent. Desonide favored sensitive sites compared with high potency agents. | Facial/fold long-term caution, untreated skin infection, pediatric BSA/age restrictions. | Atrophy with overuse; local burning, telangiectasia. | Flare assessment within 1 week, taper/stop on clearance. |
| Triamcinolone acetonide 0.1% / betamethasone valerate 0.05–0.1% (moderate Rx) | Thin layer 1–2 times/day to trunk/limb patches for ~7–14 days, then stop or intermittent maintenance if prescribed. Product potency differs by ointment vs cream. | Avoid face/genitals/folds unless specifically directed, age-specific restrictions, wide areas/occlusion. | Atrophy, stretch marks, hypopigmentation, systemic absorption; DDIs minimal except additive corticosteroid exposure. | Response 3–7 days, skin thinning with repeated use, frequency of flares. |
| Mometasone furoate 0.1% / clobetasol 0.05% (higher-potency Rx; selected cases only) | Mometasone thin layer usually once daily limited course; clobetasol 0.05% very high potency typically once or twice daily ≤2 weeks on thick resistant adult plaques only. | Not routine MACS for delicate areas, infants, or widespread disease. Avoid infection/occlusion; confirm product-specific potency. | HPA-axis suppression, atrophy, folliculitis; cataract/glaucoma risk near eyes, tachyphylaxis concern. | Recheck high potency within 1–2 weeks; stop/step down when controlled. |
| Tacrolimus ointment 0.03% / 0.1% (topical calcineurin inhibitor; Rx) | 0.03% for age ≥2–15 years; 0.03% or 0.1% age ≥16 years; thin layer twice daily to active lesions until control; intermittent proactive use may be prescribed. | Not for <2 yr per typical Canadian label, severe immunodeficiency, active cutaneous infection; avoid excessive UV exposure. | Transient burning/stinging; avoid concomitant UV phototherapy; minimal systemic DDIs. | Reassess 1–2 weeks for burning and improvement, sustained control at 4–6 weeks. |
| Pimecrolimus 1% cream (Elidel; Rx topical) | Thin layer twice daily to eczema until clear, intermittent use for recurrence; review age/label and BC prescriber scope. | Do not use on infected lesions; age restrictions per Canadian monograph; avoid immunocompromised states. | Stinging/warmth, transient erythema; avoid strong UV exposure; limited systemic interactions. | Improvement 1–3 weeks, if no clear response by 6 weeks reevaluate. |
| Dupilumab / JAK inhibitors / systemic immunomodulators (specialist-only context) | Moderate–severe refractory eczema requires dermatology-directed biologic/systemic regimens and pre-treatment screening; no generic short OTC/MACS regimen. | Not part of topical MACS prescribing for dermatitis. | Agent-dependent infection/thrombosis/lab and other risks. | Specialist monitoring schedule, labs and infection/vaccine review as indicated. |
17 | Allergic and irritant contact dermatitis
BC MACS: dermatitis — topical Schedule I drugs for low-risk mild casesLecture basis: DERM 13 slides 66–81Risk factors / causes
Exposure to soaps, sanitizers, wet work, household detergents, nickel/jewellery, fragrance, preservatives, hair dye, plants, gloves/latex, topical medication. Allergic dermatitis is delayed T-cell (type IV) sensitization; irritant type is direct barrier damage and can occur on first exposure.
Clinical presentation / complications
Usually exposure-distributed, well-demarcated itchy eczematous rash; allergic reaction appears ~24–48h after reexposure with itch prominent; irritant reaction often more burning/pain, dryness, fissures. Acute vesicles/bullae or crust; chronic lichenification. Complications: infection, occupational hand dermatitis, pigment change.
Refer / do not self-treat
Refer if >20% BSA, eyelids/genitals/face severely involved, severe blistering/ulceration, fever/spreading pus, systemic allergic symptoms, uncertain culprit, occupational recurrent exposure, no improvement 1–2 weeks or severe persistent hand eczema. Emergency for breathing difficulty/angioedema.
Goals / treatment selection
Identify and STOP offending exposure, repair skin barrier, reduce inflammation/pruritus and prevent recurrence. Patch testing for recurrent/unexplained allergic cases; distinguish irritant dermatitis from urticaria and infection.
| Drug / category / scope | Strength • dose • duration / application | Contraindications / avoid / precautions | Interactions / key adverse effects | Effectiveness + safety monitoring |
|---|---|---|---|---|
| Hydrocortisone 0.5–1% OTC topical steroid | Thin layer 1–2 times daily for ~5–7 days on mild limited face/folds/children if appropriate; short body course up to 1–2 wk. | Do not apply to open infected lesions; avoid chronic face/genital use. | Local irritation, atrophy with prolonged use; little drug-drug interaction. | Pruritus/rash at 3–7 d; refer if spreading or not resolving. |
| Triamcinolone 0.1%, betamethasone valerate 0.05–0.1% (moderate Rx) | Apply thin layer 1–2 times per day for ~7–14 days to trunk/hands/extremities with careful site assessment. | Not for uncontrolled infection or sensitive sites without clinician decision; steroid allergy possible. | Atrophy, hypopigmentation, striae; repeated exposure large-area systemic absorption. | Response at 3–7 d; discontinue/step down once cleared. |
| Clobetasol 0.05% (very high-potency Rx; severe thick hand/palm lesions) | Small amount to limited thick adult skin 1–2 times/day for ≤2 weeks, ONLY if appropriate prescriber assessment; generally not minor routine case. | Avoid face/folds, younger children, occlusion, extensive body coverage. | Atrophy, HPA suppression, superinfection; systemic corticosteroid burden. | Review 1–2 wk; refractory severe cases dermatology referral. |
| Tacrolimus 0.03–0.1% / pimecrolimus 1% (Rx, off-label some sites) | Applied twice daily to selected recurrent sensitive-site eczematous lesions under an accepted clinical approach; site, age and label must be checked. | Uncertain diagnosis, active infection, immunosuppression; exposure allergy must be removed first. | Transient burning; ultraviolet avoidance; limited systemic DDIs. | Review by 2 weeks; escalate if persistent trigger or infection. |
| Oral nonsedating antihistamine (OTC symptom relief only) | Cetirizine 10 mg PO daily or loratadine 10 mg daily as needed for concomitant urticaria/allergic symptoms; often little effect on eczematous itch itself. | Renal impairment requires cetirizine review; age/weight and pregnancy vary. | Cetirizine somnolence; minimal interactions, alcohol additive sedation in some. | Symptom relief in 1–3 days; discontinue if not helpful. |
| Prednisone / systemic corticosteroid (other prescriber, extensive allergic reactions) | Physician may prescribe short taper for severe widespread allergic contact dermatitis, especially rhus dermatitis; not a dermatitis TOPICAL-MACS drug. | Infection, diabetes, GI/psychiatric complications, rebound with too-short courses. | Hyperglycemia, insomnia, fluid retention, drug interactions. | Physician-directed monitoring and taper according to severity. |
18 | Acne vulgaris — sourced from Acne.pdf
BC MACS: mild acne — TOPICAL Schedule I drugs only (dedicated acne lecture pending)Source: dedicated Acne.pdf (CPhA eTherapeutics print, 2022; pages 1–16)Risk factors / causes
Pubertal androgen-driven sebum, follicular hyperkeratinization, Cutibacterium acnes and inflammation; family history, occlusive cosmetics/masks, hormonal shifts, corticosteroids, lithium, anabolic agents; may persist into adulthood.
Clinical presentation / complications
Open/closed comedones plus inflammatory papules/pustules on face/chest/back; nodules/cysts suggest severe disease. Rosacea has central redness/telangiectasia and NO comedones. Complications: permanent scarring, post-inflammatory dyschromia and psychosocial distress.
Refer / do not self-treat
Refer deep nodules/cysts, rapid severe acne, scarring, major psychological distress, suspected endocrine hyperandrogenism, pregnancy when Rx options limited, failure after 8–12 weeks of correctly used topical therapy or widespread severe disease.
Goals / treatment selection
Reduce comedones and inflammatory lesions, prevent scars and pigmentation; start with BPO or topical retinoid, and avoid antibiotic monotherapy. Visible response generally 6–8 weeks; 8–12-week assessment essential.
| Drug / category / scope | Strength • dose • duration / application | Contraindications / avoid / precautions | Interactions / key adverse effects | Effectiveness + safety monitoring |
|---|---|---|---|---|
| Benzoyl peroxide 2.5% / 5% / 10% (OTC) | Thin layer once daily initially; increase to twice daily as tolerated. Lower 2.5–5% often similarly effective with less irritation; use 8–12 weeks then maintenance. | Avoid allergy/severely inflamed broken skin; caution delicate areas. | Dryness, bleaching clothing/hair, irritant/contact dermatitis; can oxidize tretinoin formulations—separate applications unless stabilized combination. | Dryness at 1–2 weeks; lesion count at weeks 6–8; benefit at 8–12 weeks. |
| Adapalene 0.1% / 0.3% gel or cream (Differin; Schedule I topical MACS) | Thin layer to acne-prone skin once nightly; start 2–3 nights/wk then increase as tolerated for 8–12 wk. Adapalene 0.1% + BPO 2.5% combo (TactuPump) nightly. | Avoid during pregnancy/planning pregnancy; severe eczema/sunburn or skin sensitivity. | Dryness, peeling, photosensitivity/irritation; avoid concurrent harsh exfoliants; BPO combo bleaches fabrics. | Tolerance 2–4 weeks; comedones and inflammatory lesions by weeks 6–12. |
| Tretinoin 0.01%, 0.025%, 0.05%, 0.1% topical (Schedule I MACS) | Pea-sized thin layer once nightly to dry acne-prone skin for ≥8–12 wk; titrate strength and frequency slowly. | Pregnancy avoidance, sunburn/eczema, topical sensitization; age restrictions per formulation. | Irritation, erythema, peeling, photosensitivity; separate traditional tretinoin application from BPO if formulation not compatible. | Skin irritation weeks 1–4, acne at 8–12 wk. |
| Clindamycin 1% topical (Rx Schedule I; use WITH BPO) | Thin layer once or twice daily as directed; often paired with BPO 3–5% (e.g. Clindoxyl) once daily for inflammatory acne. LIMIT antibiotic to ~8–12 weeks then nonantibiotic maintenance. | Do not use as monotherapy; history of antibiotic-associated colitis/IBD and severe hypersensitivity require caution. | Local dryness, rare antibiotic-associated diarrhea/colitis; combination with BPO reduces resistance. | Inflammatory lesions at 6–8 weeks, diarrhea during treatment; stop if severe. |
| Azelaic acid 15% gel (Finacea; topical MACS) | Apply thin layer once or twice daily to acne-prone skin per label and tolerance for 8–12 wk; may help post-inflammatory pigmentation. | Skin sensitization; avoid eyes/mucous membranes. | Stinging, burning, dryness; few systemic DDIs. | Tolerance 1–2 wk; inflammatory lesion response weeks 6–12. |
| Dapsone 5% topical gel (Aczone; Schedule I MACS) | Thin layer twice daily for inflammatory acne, if Canadian product available and suitable; verify DIN/age. | G6PD deficiency/hemolysis caution; use with BPO can transiently stain skin/hair orange-brown. | Dryness, local oiliness, rare hematologic effects with systemic absorption. | Inflammatory lesions 8–12 weeks; hematologic symptoms in risk patients. |
| Oral doxycycline, isotretinoin, hormonal agents (other prescriber ONLY) | Moderate/severe inflammatory or scarring acne may need systemic therapy, but not permitted under topical-only BC acne MACS. | Pregnancy restrictions and agent-specific serious adverse effects. | Systemic monitoring required, especially isotretinoin teratogenicity. | Referral to primary care/dermatology for treatment planning. |
19 | Acute rhinosinusitis / sinusitis
OTC management · systemic antibiotics outside BC MACSSource: HEENT 06 Sinusitis, pages 4–45Risk factors / etiology
Recent viral URI; allergic rhinitis/asthma; smoking or second-hand smoke; nasal polyps, septal abnormalities, impaired drainage, immunosuppression; daycare/recent antibiotics may raise resistant-pathogen concerns.
Presentation / differential / complications
PODS: Pain/pressure face, Obstruction, purulent Discharge, Smell change; plus cough, dental/ear pressure, malaise. Likely viral: <10 days and improving. Suspect bacterial: ≥10 days without improvement, severe fever ≥39°C with purulent discharge/facial pain ≥3–4 days, or double worsening after initial improvement. Discharge colour alone is not diagnostic. Complications: orbital cellulitis, intracranial abscess/meningitis.
When to refer / scope limit
Emergency: orbital pain/swelling, impaired vision/diplopia, proptosis, altered mental status, severe headache with stiff neck, neurologic signs. Medical assessment: bacterial pattern, severe facial pain, prolonged fever, immunocompromise, recurrent episodes ≥4/year, chronic symptoms ≥12 weeks, significant comorbidity. BC sinusitis is not a MACS prescribing diagnosis; antibiotic selection belongs to another authorized prescriber.
Goals of therapy
Relieve facial pain/congestion, improve drainage and sleep, prevent serious complication, avoid unnecessary antibiotic exposure and resistance.
| Drug / category / scope | Strength • dose • frequency • duration | Contraindications / avoid / precautions | Adverse effects / important interactions | Monitoring and timing |
|---|---|---|---|---|
| Saline nasal spray / isotonic rinse (OTC) | 0.9% NaCl spray: 1–2 sprays/nostril PRN several times/day; high-volume saline rinse per device (often once or twice daily), as tolerated. | Do not use unboiled tap water; avoid vigorous irrigation with complete blockage/ear discomfort. | Transient irritation, minor burning or ear pressure; no significant systemic DDIs. | Check nasal obstruction/discharge in 48–72 h; discontinue if ear pain/bleeding. |
| Fluticasone propionate intranasal (OTC/Rx) | 50 micrograms/spray: 1–2 sprays/nostril once daily (usual adult range) for 1–2 weeks if indicated; maximal effect 3–14 d. | Caution recent nasal surgery/ulcers, recurrent epistaxis, untreated nasal infection; not an antibacterial drug. | Epistaxis, dryness, headache; CYP3A4 inhibitors (e.g., ritonavir) may increase systemic steroid exposure. | Reassess at 72 h; inspect for persistent epistaxis and pain at 1–2 weeks. |
| Oxymetazoline topical nasal (OTC) | 0.05%: commonly 1–2 sprays/nostril q12h as needed; maximum 3 days (confirm label). | Uncontrolled HTN, significant CAD/arrhythmia, hyperthyroidism, glaucoma; pregnancy individualize; avoid with MAOI. | Rebound congestion/rhinitis medicamentosa with prolonged use; dryness, palpitations. | Stop by day 3; return if congestion rebounds. |
| Pseudoephedrine oral (OTC, age/product restricted) | Immediate release 30–60 mg PO q4–6h as needed; max 240 mg/day adult; use only for a few days. | Uncontrolled HTN, CAD, severe arrhythmia, glaucoma, urinary retention; avoid MAOI within 14 days. | Insomnia, nervousness, increased BP/HR; additive stimulants and sympathomimetics. | Ask about BP/palpitations/sleep within 1–2 days; stop if marked symptoms. |
| Acetaminophen / ibuprofen (OTC) | Acetaminophen 500–1000 mg PO q6–8h PRN, conservative self-care max 3000 mg/day; ibuprofen 200–400 mg PO q4–6h PRN, max OTC 1200 mg/day. Short-term. | Acetaminophen: major liver disease/heavy alcohol. Ibuprofen: ulcer/bleeding, CKD, dehydration, late pregnancy; avoid other NSAIDs. | Acetaminophen: liver toxicity in overdose/combination products. NSAID: dyspepsia, AKI, GI bleed; interactions warfarin/ACEI/diuretic. | Pain/fever over 48–72 h; if worsening seek assessment. |
| Amoxicillin (clinician-directed, NOT BC sinusitis MACS) | Pediatric regimen in uploaded lecture: 40 mg/kg/day divided TID ×10 days; high dose 90 mg/kg/day divided BID–TID ×10 days for selected risk. Adult dose requires local guideline/product verification. | Penicillin anaphylaxis; dose adjust for renal function; assess severity, recent antibiotics and bacterial features first. | Rash, diarrhea, hypersensitivity; increased INR possible with warfarin; some severe delayed reactions. | Clinician follow-up for worsening after 72 h on antibiotics or nonresponse after course. |
| Amoxicillin/clavulanate (clinician-directed) | Lecture failure option adult 875/125 mg PO BID ×5–10 days; pediatric 7:1 formulation 45 mg/kg/day of amoxicillin component divided BID–TID ×10 days, with extra amoxicillin for selected high-dose plans. | Penicillin allergy, previous amoxicillin-clavulanate cholestatic jaundice; renal/hepatic caution. | Diarrhea, nausea, candidiasis, rare liver injury; interaction with warfarin (INR); C. difficile. | Review treatment response by 48–72 h and adverse effects throughout; culture/referral if failure. |
| Levofloxacin (clinician/specialist reserve) | Lecture treatment-failure option 750 mg PO daily ×5–10 days (renal adjustment); reserve when alternatives unsuitable. | Myasthenia gravis, prior quinolone tendon disorder, QT risk, pregnancy/children; many serious warnings. | Tendinitis/rupture, neuropathy, CNS effects, dysglycemia, QT prolongation; chelation with iron/calcium/magnesium. | Close follow-up for tendon/neurologic symptoms, QT/renal concerns; not routine initial care. |
20 | Allergic rhinitis (seasonal / perennial)
BC MACS: intranasal + oral antihistamines + specified ophthalmic drugsSource: HEENT 07 Allergic Rhinitis, pages 3–34, 44Risk factors / etiology
Genetic/atopic history, asthma, eczema; seasonal tree/grass/weed pollen and molds; perennial mites, pets and occupational allergens. Exposure intensity, indoor humidity/ventilation contribute.
Presentation / differential / complications
IgE-mediated: sneezing, nasal and eye itch, clear rhinorrhea, congestion, postnasal cough; allergic shiners, watery eyes. Early histamine phase and later congestive inflammatory phase. Intermittent vs persistent (>4 days/week AND >4 weeks); mild vs moderate/severe (sleep/activity impairment). Complications include disrupted sleep/productivity, sinus/ear symptoms and asthma destabilization.
When to refer / scope limit
Unilateral foul discharge/bleeding, high fever, facial pain, nasal polyp/obstruction, suspected foreign body, severe asthma, symptoms atypical for allergy, treatment failure after optimized 2–4 weeks; urgent swelling/breathing compromise.
Goals of therapy
Relieve itch, sneezing, rhinorrhea and obstruction; preserve sleep/function and asthma control; minimum effective continuous therapy.
| Drug / category / scope | Strength • dose • frequency • duration | Contraindications / avoid / precautions | Adverse effects / important interactions | Monitoring and timing |
|---|---|---|---|---|
| Fluticasone propionate / furoate (INCS; MACS if Schedule I) | Propionate 50 mcg/spray 1–2 sprays/nostril daily; furoate 27.5 mcg/spray 2 sprays/nostril daily initially then 1 when controlled. Review individual Canadian labels. | Recent nasal surgery, recurrent bleeding; review interacting strong CYP3A4 inhibitors. | Epistaxis, irritation, headache; rarely perforation or thrush. Strong CYP3A4 inhibition may increase systemic exposure. | Check technique/adherence at day 3–7; maximal response at day 3–14; reassess 2–4 weeks. |
| Mometasone / ciclesonide INCS (MACS if Schedule I) | Mometasone 50 mcg/spray 1–2 sprays/nostril daily; ciclesonide 50 mcg/spray 2 sprays/nostril daily (lecture). | Nasal ulceration, severe recurrent nosebleeds and untreated nasal infection; pregnancy individualized. | Epistaxis, local irritation; low systemic bioavailability. | Technique day 3–7 and control after 2 weeks. |
| Budesonide / triamcinolone / beclomethasone INCS | Budesonide 1–2 sprays/nostril daily; triamcinolone 1–2 sprays/nostril daily; beclomethasone 1–2 sprays/nostril BID; strength varies by device. | Local nasal infection/ulceration and recent surgery. In pregnancy, lecture recommends avoiding triamcinolone relative to others. | Nosebleeds, irritation, rarely septal perforation. | Monitor local tolerance first week, effect at 1–2 weeks, longer-term necessity/lowest dose. |
| Cetirizine (2nd-generation H1; OTC) | 10 mg PO daily adult; pediatric dose differs. May be used PRN for intermittent mild symptoms. | Renal impairment needs dose reduction; caution driving/sedation and use with alcohol. | Somnolence (relatively more than other second-gen), dry mouth; additive sedatives. | Itch/sneezing after 1–2 days; sedation/renal considerations at first follow-up. |
| Loratadine / desloratadine (2nd-gen H1) | Loratadine 10 mg PO daily; desloratadine 5 mg PO daily adult. | Renal/hepatic impairment or interactions may require review; age-specific labeling. | Headache, xerostomia, usually little sedation; possible CYP interactions with certain inhibitors. | Assess nasal/ocular symptoms in 3–7 days and adverse effects. |
| Fexofenadine / bilastine / rupatadine (2nd-gen H1) | Fexofenadine 60 mg PO BID or 120 mg daily (lecture); bilastine 20 mg daily on empty stomach; rupatadine 10 mg daily adult. | Bilastine food/fruit juice reduce exposure; caution renal failure + P-gp inhibitors; rupatadine CYP3A4 inhibitors/grapefruit. | Headache, occasional somnolence; fexofenadine separated from Al/Mg antacids by ≥2 h. | Review effect by 3–7 days and medication timing/food effects. |
| Azelastine 137 mcg + fluticasone 50 mcg spray (Dymista; MACS) | 1 spray per nostril BID; daily during allergen exposure; step-up after insufficient INCS response. | Nasal trauma, severe epistaxis; sedative use and CYP3A4 inhibitors. | Bitter taste, epistaxis, occasional sedation; local irritation. | Reassess 3–7 days; check bitterness technique and nosebleeds. |
| Olopatadine 665 mcg + mometasone 25 mcg spray (Ryaltris; MACS) | 2 sprays per nostril BID per lecture; product/age verification required. | Avoid significant recent nasal trauma, severe epistaxis; age and pregnancy per monograph. | Dysgeusia, epistaxis, headache; additive intranasal steroid effects. | Reassess in 3–7 days; ongoing symptom score. |
| Ipratropium nasal (other Rx, verify indication/scope) | 0.03% nasal solution: often 2 sprays/nostril BID–TID for prominent watery rhinorrhea; does NOT reliably reduce congestion. | Glaucoma or urinary retention caution; avoid spraying into eyes. | Nasal dryness/bleeding; anticholinergic effects mostly local. | Rhinorrhea in days; assess nasal dryness/bleeding. |
| Decongestants: oxymetazoline / pseudoephedrine (OTC) | Oxymetazoline 0.05%, 1–2 sprays/nostril BID ≤3 days; pseudoephedrine adult 30–60 mg q4–6h PRN, max 240 mg/day; temporary rescue only. | Avoid uncontrolled HTN, cardiovascular disease, glaucoma, recent MAOI; caution BPH/retention, pregnancy. | Insomnia, hypertension, palpitations; rebound congestion with nasal decongestants >3 days. | Check by 48–72 h; switch to INCS rather than prolonging decongestant. |
21 | Pharyngitis / sore throat / confirmed GAS
OTC supportive · systemic antibiotics NOT BC MACSSource: HEENT 08 Pharyngitis, pages 10–35 + Canadian Paediatric Society/CDC guidanceRisk factors / etiology
School-age child (GAS peak 5–15 y), household/daycare contact, winter/spring, crowding; viral URI exposures. Immunocompromised or previous rheumatic fever can alter threshold for investigation.
Presentation / differential / complications
Viral clues: cough, coryza, hoarseness, conjunctivitis, oral ulcers, diarrhea. GAS clues: sudden severe sore throat, fever ≥38°C, tender anterior neck nodes, tonsillar exudate, absence of cough, palatal petechiae, scarlet-fever rash. Centor/McIsaac estimates need for testing, not a definitive diagnosis. Complications: abscess, otitis, rheumatic fever, post-streptococcal glomerulonephritis.
When to refer / scope limit
Emergency: drooling, stridor, respiratory distress, muffled/hot-potato voice, trismus, unilateral tonsillar swelling/uvular displacement, cannot swallow secretions, neck swelling, dehydration. Testing/physician visit for likely GAS, persistent/worsening ≥4–5 days, immunosuppression. Do not prescribe systemic antibiotics under BC MACS for pharyngitis.
Goals of therapy
Control painful swallowing and fever, maintain hydration/nutrition; for confirmed GAS, prevent rheumatic fever/complications and transmission.
| Drug / category / scope | Strength • dose • frequency • duration | Contraindications / avoid / precautions | Adverse effects / important interactions | Monitoring and timing |
|---|---|---|---|---|
| Acetaminophen / ibuprofen (OTC) | Acetaminophen adult 500–1000 mg PO q6–8h PRN (max conservative 3000 mg/day); ibuprofen 200–400 mg q4–6h PRN (OTC max 1200 mg/day). Pediatric dosing by weight, separate guide/label. | Ibuprofen avoid ulcer/GI bleed, CKD/dehydration, late pregnancy, NSAID allergy. Acetaminophen severe liver disease; watch combo cold products. | GI upset, AKI/bleed (NSAIDs), hepatic toxicity from acetaminophen overdose; interactions anticoagulants and ACEI/diuretics. | Reassess fever/pain after 24–48 h; fever >3 days or worsening refer. |
| Benzocaine/phenol topical throat products (OTC) | Benzocaine lozenge or spray, phenol spray: dose per labelled formulation, brief pain relief ~30–45 min. Not a substitute for evaluation. | Benzocaine: methemoglobinemia risk, avoid young children; lozenges choking hazard; avoid local anesthetic allergy. | Numbness, hypersensitivity; rare cyanosis/methemoglobinemia (benzocaine). | Monitor swallowing, numbness and breathing; stop urgently with blue/grey colour. |
| Penicillin V (confirmed GAS, other prescriber) | Lecture: adults >27 kg 300 mg PO TID or 600 mg BID ×10 days. Current CDC option: adults 500 mg BID or 250 mg QID ×10 days. Verify local Canadian product strengths. | Immediate penicillin allergy, severe prior beta-lactam reaction; renal adjustment if needed. | Diarrhea, rash, anaphylaxis; consider interactions with warfarin and methotrexate. | Symptoms should improve within 24–72 h; complete 10 days; refer if no improvement after 48–72 h. |
| Amoxicillin (confirmed GAS, other prescriber) | Adults 500 mg PO BID ×10 days (lecture). Child 25 mg/kg/dose BID (max 500 mg/dose) or 50 mg/kg once daily (max 1 g/day) ×10 days per CDC. | Penicillin allergy; suspected mononucleosis may provoke rash; renal impairment. | Rash, nausea, diarrhea; anaphylaxis and C. difficile possible. | Improvement in 48–72 h; monitor allergy and hydration. |
| Cephalexin (penicillin allergy NON-immediate only) | Adults 500 mg PO BID ×10 days; child 20 mg/kg/dose BID (max 500 mg/dose) ×10 days. | Avoid with immediate/anaphylactic penicillin hypersensitivity or cephalosporin allergy; renal adjust. | Diarrhea/rash; warfarin can alter INR; C. difficile rare. | Improvement in 48–72 h; allergy/diarrhea during course. |
| Clindamycin (severe penicillin allergy option) | Adults 300 mg PO TID ×10 days; child 7 mg/kg/dose TID (max 300 mg/dose) ×10 days. Consider local resistance. | Previous C. difficile/antibiotic-associated colitis, severe allergy. | Diarrhea and high C. difficile risk; esophagitis if not taken with water. | Urgent review for frequent watery/bloody diarrhea; symptoms by 48–72 h. |
| Clarithromycin (penicillin allergy alternative) | Adults 250 mg PO BID ×10 days; child 7.5 mg/kg/dose BID (max 250 mg/dose) ×10 days. | Prolonged QT, important CYP3A4 interacting drugs (e.g. statins, certain anticoagulants), severe hepatic issues. | Dysgeusia, GI upset, QT prolongation; strong CYP3A4 inhibition. | Check DDIs BEFORE dosing; review improvement at 48–72 h. |
| Azithromycin (penicillin allergy alternative) | Lecture gives 500 mg PO daily ×3 days (adults), 20 mg/kg/day ×3 days pediatric; alternative guideline CDC: 500 mg day 1 then 250 mg daily days 2–5 adult. Choose local regimen, not both. | QT prolongation, major macrolide allergy, resistant GAS prevalence. | GI upset, QT prolongation; interactions with other QT-prolonging medicines. | Reassess in 48–72 h and for recurrent symptoms after course. |
| Dexamethasone single dose (clinician-directed, NOT routine) | Lecture mentions 10 mg PO once adults or 0.6 mg/kg PO once children; not routine recommendation. | Diabetes, infection, GI bleeding, immunosuppression; risk–benefit needs clinician. | Transient hyperglycemia, insomnia, agitation; additive effects with NSAIDs. | Assess pain benefit over 24–48 h; not an alternative to appropriate diagnosis. |
22 | Common cold / viral upper respiratory tract infection
OTC symptomatic · no BC MACS cold diagnosisSource: RESP 16 Cough and Cold, pages 8–24, 39–45Risk factors / etiology
Frequent close contacts/daycare, crowded indoor exposure, tobacco smoke, poor sleep; children and immunocompromised may have more frequent or severe episodes.
Presentation / differential / complications
Viral URI (rhinovirus, coronavirus, RSV etc.): sore throat first, nasal rhinorrhea/congestion, sneezing, mild short fever, then cough that may persist up to 3 weeks. Normal course improves within 7–10 days. Purulent or coloured sputum alone is not proof of bacteria. Complications: secondary otitis/sinusitis, exacerbation of asthma/COPD, dehydration.
When to refer / scope limit
Emergency: difficulty breathing, cyanosis, chest pain, confusion, meningism, dehydration in infant. Medical review if fever >3 days, severe unilateral ear pain, high-risk immunocompromise, severe/worsening illness, cough >3 weeks or asthma/COPD deterioration; consider influenza/COVID if testing or treatment indicated.
Goals of therapy
Short-term comfort and sleep while illness self-resolves; avoid duplicate ingredients and unnecessary antibiotics.
| Drug / category / scope | Strength • dose • frequency • duration | Contraindications / avoid / precautions | Adverse effects / important interactions | Monitoring and timing |
|---|---|---|---|---|
| Acetaminophen for fever/pain (OTC) | Adult 500–1000 mg PO q6–8h PRN, prudent OTC ceiling 3000 mg/day from all products; follow exact package ceiling and clinician advice. | Advanced hepatic disease, chronic heavy alcohol use; avoid double-dosing in combination cold products. | Liver toxicity with overdose; may raise INR if repeated higher doses with warfarin. | Fever and comfort over 24–48 h; fever continuing >3 days merits referral. |
| Ibuprofen for pain/fever (OTC) | Adult 200–400 mg PO q4–6h PRN with food; OTC max 1200 mg/day; shortest course. | NSAID allergy, GI bleeding/ulcer, advanced CKD, significant dehydration, late pregnancy. | Dyspepsia/bleeding, renal injury, edema; interactions anticoagulants, ACEI/ARB plus diuretic, SSRIs. | Pain/fever and GI/renal tolerance over first 2–3 days. |
| Oxymetazoline topical decongestant (OTC) | 0.05% adult 1–2 sprays/nostril q12h as needed for congestion; ≤3 days. | Glaucoma, uncontrolled HTN, CAD, MAOIs; age-specific label and pregnancy considerations. | Rebound rhinitis, dry nose, sympathomimetic effects. | Check at 48–72 h and STOP by day 3. |
| Pseudoephedrine oral decongestant (OTC) | 30–60 mg PO q4–6h adult PRN, max 240 mg/day; only brief use for congestion. | Uncontrolled HTN, cardiac arrhythmia, coronary disease, MAOI, urinary retention/BPH, narrow-angle glaucoma. | Palpitations, nervousness, insomnia, elevated BP; stimulant interactions. | Reassess benefit/HR/BP and insomnia within 1–2 days. |
| Ipratropium nasal 0.03% (Rx outside cold MACS) | Common rhinorrhea regimen: 2 sprays/nostril BID–TID for short period; does not improve obstructive congestion. | Anticholinergic-sensitive glaucoma/retention; avoid eyes. | Local dryness/epistaxis; low systemic exposure. | Monitor watery nasal drainage over 2–3 days. |
| Diphenhydramine 25–50 mg (OTC; generally avoid for URI) | Adult often 25–50 mg PO q4–6h (max product label); not routinely recommended for viral cold due to marginal benefit/anticholinergic burden. | Older adults, glaucoma, urinary retention, sedatives, driving, young children. | Drowsiness, confusion, xerostomia, falls; additive anticholinergics/alcohol. | Reconsider after first dose; avoid routine ongoing use. |
| Oral phenylephrine (OTC in some combos) | Common labelled adult 10 mg PO q4h, but oral efficacy for congestion is not established; prefer other options. | Cardiovascular disease, HTN, MAOI; check product label. | Insomnia, BP increase; stimulant interaction. | Avoid ineffective combination products; reassess within 1–2 days. |
23 | Cough: dry, productive, postviral and red flags
OTC symptom management · no standalone BC MACS cough diagnosisSource: RESP 16 Cough and Cold, pages 15–45Risk factors / etiology
Postviral airway irritation, smoking/vaping, asthma/COPD, GERD, postnasal drainage; ACE inhibitors and environmental irritants. High-risk context: heart failure, immunosuppression, TB exposure.
Presentation / differential / complications
Dry: tickling nonproductive cough (often worse at night); productive: sputum with possible viral URI; postinfectious may last 3–8 weeks (needs workup depending on pattern). Complications: sleep disturbance, dehydration, musculoskeletal pain; a “wet cough” with dyspnea may be pneumonia or COPD exacerbation.
When to refer / scope limit
Urgent: hypoxia, marked dyspnea, hemoptysis, chest pain, confusion, suspected pneumonia, severe asthma/COPD exacerbation. Assessment for cough >3 weeks, persistent fever, recurrent/worsening illness, significant risk factors, weight loss/night sweats. ACE inhibitor cough merits medication review; do not suppress symptoms of COPD exacerbation.
Goals of therapy
Soothe throat and improve sleep; limit treatment to short symptom-directed trials while treating or investigating cause.
| Drug / category / scope | Strength • dose • frequency • duration | Contraindications / avoid / precautions | Adverse effects / important interactions | Monitoring and timing |
|---|---|---|---|---|
| Dextromethorphan (DM; OTC) for disruptive dry cough | Adult immediate-release 10–20 mg PO q4h or 30 mg q6–8h; max 120 mg/day (all products). Prefer bedtime-only if occasional symptoms. | Avoid MAOI (including linezolid/methylene blue) within 14 days, strong serotonergic co-medications, severe respiratory illness requiring evaluation; check age/product. | Dizziness, drowsiness, nausea; serotonin syndrome with SSRI/SNRI/MAOI or CYP2D6 inhibitors increasing exposure; abuse potential. | Judge benefit by 1–3 nights; stop if no benefit or serotonin toxicity symptoms. |
| Guaifenesin (OTC) for bothersome thick sputum | Adult IR 200–400 mg PO q4h as needed (max 2400 mg/day); ER 600–1200 mg PO q12h (max 2400 mg/day), with fluids. | Persistent purulent sputum plus fever/dyspnea needs evaluation; do not mask pneumonia/COPD flare. | Nausea, dizziness; few major interactions; limited evidence for meaningful improvement. | Trial 2–3 days; review sputum, cough function and new red flags. |
| Honey (non-drug) | Age ≥1 year: 2.5–5 mL (½–1 tsp) at bedtime for troublesome cough, as desired; dental hygiene. | Absolute avoid in infants <12 months; sugar considerations in diabetes. | Usually mild GI effects; no drug interaction expected. | Benefit overnight; discontinue if no relief. |
| Diphenhydramine / doxylamine (OTC night products) | Not first-line antitussives; doses depend on age/product; avoid simply to induce sleep. Many combo preparations contain analgesic + antitussive. | Older adults, glaucoma, retention, alcohol/sedatives, fall risk; avoid paediatric cough/cold products under 6. | Daytime sedation, anticholinergic effects, falls/delirium; additive CNS depressants. | Review first dose; stop with confusion, severe sedation or poor function. |
| Inhaled bronchodilator or controller (prescription) | Not an OTC cough remedy. Wheezing/dyspnea in known asthma/COPD → review action plan and prescribed inhalers; new symptoms require assessment. | No diagnosis of asthma/COPD solely from a cough complaint. | Tremor/tachycardia with short-acting beta-agonist; steroids may cause thrush with inappropriate technique. | Reassess airway symptoms promptly; escalating reliever need requires medical review. |
24 | Conjunctivitis: bacterial, viral and allergic
BC MACS: ophthalmic drugs for allergic, bacterial or viral conjunctivitisSource: HEENT 15 Conjunctivitis, pages 7–65Risk factors / etiology
Close contacts with red eye, recent URI, daycare, shared cosmetics/towels, contact lenses/poor lens hygiene; allergic rhinitis/seasonal exposures, eczema; HSV exposure/immunocompromise increase risk.
Presentation / differential / complications
Bacterial: diffuse redness, mucopurulent discharge and stuck eyelids, often mild irritation; viral: watery discharge, URI, preauricular nodes, often unilateral then bilateral; allergic: dominant itch, bilateral watery/stringy discharge, seasonal triggers. Complications: keratitis/corneal ulcer, scarring, significant vision loss (rare), hyperacute gonococcal infection.
When to refer / scope limit
Same-day urgent eye evaluation: contact lens wearer with red painful eye, photophobia, visual loss, significant pain, corneal opacity, ciliary flush, abnormal pupil, ocular HSV/zoster, injury/chemical exposure, severe purulence, neonate, suspected gonococcal disease. Also refer recurrent/chronic >4 weeks or nonresponse at 48 h. Do not treat potential corneal ulcer as simple MACS conjunctivitis.
Goals of therapy
Preserve vision, relieve discomfort/discharge, manage allergic triggers, prevent transmission; use antibiotics only when bacterial infection is likely/appropriate.
| Drug / category / scope | Strength • dose • frequency • duration | Contraindications / avoid / precautions | Adverse effects / important interactions | Monitoring and timing |
|---|---|---|---|---|
| Polymyxin B/gramicidin/bacitracin combinations (OTC ophthalmic; product dependent) | Polysporin Eye/Ear drops: label may direct 1–2 drops in affected eye up to 4–6 times/day; lecture gives initial frequent 1–3 drops then taper. Ophthalmic ointment 2–5 times/day; verify actual DIN and indication. | Bacitracin/polymyxin allergy; avoid contact lenses and corneal ulcers; ensure ophthalmic formulation. | Transient stinging, contact allergy; no major systemic DDIs. | Reassess discharge and pain in 24–48 h; worsening triggers referral. |
| Polymyxin B + trimethoprim (ophthalmic Rx/MACS if Schedule I) | Typical 10,000 units/mL + 1 mg/mL drops: lecture titrates 1–3 drops initially at frequent intervals then 1–2 drops 4–6×/day; actual product label governs duration. | Known allergy to either component, corneal disease/trauma, contact lens-associated red eye. | Stinging, eyelid swelling/contact dermatitis; minimal systemic DDIs. | Expect improving discharge in 48 h; urgent referral if photophobia or vision change. |
| Fusidic acid 1% viscous ophthalmic drops (Fucithalmic; Rx/MACS) | 1 drop affected eye BID ×7 days per lecture/label; verify local product availability. | Hypersensitivity, ocular keratitis or uncertain diagnosis. | Transient burning, blurred vision, local allergy; low systemic DDIs. | Reassess day 2; complete course if prescribed, refer if no improvement. |
| Erythromycin 0.5% ophthalmic ointment (Rx/MACS) | Lecture: apply small ribbon to affected conjunctival sac 2–6 times/day; duration per product/clinical assessment (usually ~5–7 days). | Macrolide allergy; do not use topical skin formulations in eye. | Blurred vision after application, mild burning, allergy; minimal systemic interactions. | Improve within 48–72 h; persistent photophobia or discharge refer. |
| Tobramycin 0.3% ophthalmic (Rx/MACS; selected bacterial cases) | 1–2 drops q4h for bacterial infection (lecture); ophthalmic ointment BID–TID. Duration depends on label/clinical response. | Aminoglycoside allergy; reserve after adequate red-eye assessment; pediatric dosing depends on age/product. | Stinging, hypersensitivity; prolonged use may select resistant organisms. | Reassess after 48 h; do not escalate with worsening pain or vision changes. |
| Ciprofloxacin 0.3% ophthalmic (Rx/MACS; specialist for keratitis) | Lecture bacterial conjunctivitis: 1–2 drops q2h while awake ×2 days, then 2 drops q4h while awake ×5 days; avoid routine use for uncomplicated watery eye. | Contact lens-associated keratitis requires urgent assessment; quinolone allergy. | Bitter taste, eye irritation, precipitation/white deposits; minimal systemic DDIs. | 24–48 h reassessment; refer immediately if photophobia, corneal spot or pain. |
| Ofloxacin 0.3% / moxifloxacin 0.5% (Rx/MACS) | Ofloxacin 1–2 drops q2–4h ×2 days then QID ×5 days (lecture); moxifloxacin 1 drop TID ×7 days (lecture). Verify monographs. | Quinolone allergy; avoid empiric use with unexplained visual change or painful contact lens eye. | Transient stinging, dysgeusia, rare hypersensitivity; low systemic exposure. | Clinical review at 48 h; referral if not improving. |
| Gatifloxacin ophthalmic (Rx/MACS if marketed) | Lecture: 1 drop q2h while awake up to 8×/day ×2 days, then 1 drop QID; check exact strength/formulation/DIN and duration. | Fluoroquinolone allergy; reserve for justified bacterial indication. | Burning, taste disturbance, conjunctival hyperemia. | Reassess within 48 h; check ocular pain/vision. |
| Ketotifen ophthalmic (OTC antihistamine) | 0.025%: 1 drop affected eye q8–12h (most labels BID), during exposure/while symptomatic. | Contact lens caution; do not instill over soft contacts; allergy to components. | Transient stinging, headache; negligible systemic DDIs. | Itch relief typically same day; reassess at 48–72 h. |
| Olopatadine ophthalmic (OTC/Rx depending product) | 0.1%: generally 1 drop each affected eye BID at 6–8 h intervals; 0.2% often once daily; follow strength-specific DIN. | Ocular infection/keratitis must be distinguished; contact lens restrictions per label. | Transient discomfort, headache, mild blurred vision; minimal DDIs. | Itch and tearing in 1–3 days; refer if no improvement at 1 week. |
| Sodium cromoglycate (cromolyn) ophthalmic (OTC mast-cell stabilizer) | 2% drops: lecture 1–2 drops 4–6 times/day regularly during allergen exposure; onset slower (days–weeks). | Not for rapid relief of severe eye pain or an untreated infection. | Stinging, burning; minimal systemic interactions. | Review regular adherence/effect in 1–2 weeks; not immediate rescue. |
| Naphazoline + pheniramine/antazoline drops (OTC, short term) | Combination allergy/redness drops: 1–2 drops up to QID by product; limit short-term use. | Glaucoma, severe HTN/cardiovascular disease, MAOI; caution young children and contact lens. | Rebound redness, dryness, tachycardia if systemic absorption; avoid chronic use. | Stop after a few days; refer if persistent redness. |
| Artificial tears (OTC) | Carboxymethylcellulose 0.5–1% / hypromellose / polyvinyl alcohol: 1–2 drops TID–QID or PRN per product; preservative-free if frequent use. | Hypersensitivity, avoid contaminated bottles; severe pain/visual change is not dry eye. | Brief blur/stinging; benzalkonium chloride can irritate with frequent use. | Comfort within minutes; review 48–72 h and ongoing triggers. |
25 | Blepharitis: anterior vs posterior (meibomian)
OTC lid hygiene · prescription therapy outside standalone BC MACSSource: HEENT 16 Blepharitis & Eyelid Disorders, pages 4–13Risk factors / etiology
Seborrheic dermatitis, rosacea, Demodex infestation, altered meibomian secretion, Staphylococcus colonization, contact lenses, smoking, dry eye, chronic recurrent disease.
Presentation / differential / complications
Anterior: irritation/erythema/crusts and collarettes around eyelashes; staphylococcal harder crusts, seborrheic greasy scale. Posterior: meibomian gland dysfunction, foamy/oily tears, thick secretions, burning, recurrent dry eye. Usually chronic bilateral. Complications: recurrent hordeola/chalazia, keratoconjunctivitis, corneal irritation.
When to refer / scope limit
Pain beyond mild irritation, vision change, photophobia, corneal opacity, marked unilateral swelling/cellulitis; persistent or severe disease not responding to 1–2 weeks of lid care. Blepharitis is not a separate BC MACS condition; select treatments only within actual applicable diagnosis and scope.
Goals of therapy
Break chronic inflammation/crusting cycle, restore meibomian secretion, protect tear film, reduce recurrence and antibiotic overuse.
| Drug / category / scope | Strength • dose • frequency • duration | Contraindications / avoid / precautions | Adverse effects / important interactions | Monitoring and timing |
|---|---|---|---|---|
| Warm compress + lid hygiene (non-drug FIRST LINE) | Warm compress 5–10 min, gentle massage, lid-margin cleansing daily; continue maintenance after improvement. | Avoid scalding water, vigorous rubbing with eye pain/trauma. | Overly aggressive scrubbing may worsen irritation; no DDIs. | Review crusting/itch over 1–2 weeks; continue maintenance. |
| Erythromycin 0.5% ophthalmic ointment (other authorized prescriber) | Lecture anterior blepharitis: thin ribbon to eyelid margin at bedtime ×1–2 weeks if significant bacterial component and lid hygiene insufficient. | Macrolide allergy, uncertain diagnosis; do not put dermatologic erythromycin formulation into eye. | Transient blur, burning/contact dermatitis; low systemic DDIs. | Evaluate lid inflammation at 7–14 days; stop if allergy. |
| Fusidic acid 1% ophthalmic viscous drops (other prescriber) | Lecture: 1–2 drops q12h ×1–2 weeks in anterior blepharitis if selected. | Drug allergy; uncertain bacterial indication; product availability. | Instillation discomfort/blur; negligible DDIs. | Monitor lid crusting at 1 week. |
| Doxycycline / minocycline (clinician-directed posterior refractory) | Lecture: doxycycline 100 mg PO daily or minocycline 50–100 mg PO daily, generally 2–4 weeks for moderate–severe or refractory posterior blepharitis (not first line). | Pregnancy, children below recommended age, tetracycline allergy; check photosensitivity/esophageal disease. | GI upset, photosensitivity, esophagitis; separate from iron/calcium/antacids, warfarin INR caution. | Response and tolerance after 1–2 weeks; assess need beyond 2–4 weeks. |
| Tetracycline oral (clinician-directed alternative) | Lecture 250 mg PO QID for 2–4 weeks when indicated; less convenient than doxycycline. | Pregnancy, younger children, impaired renal function, allergy; esophagitis. | GI intolerance/photosensitivity; chelation with divalent/trivalent cations. | Response in 2–4 weeks; persistent severe disease warrants specialist review. |
| Preservative-free artificial tears (OTC adjunct) | 1–2 drops per eye TID–QID or PRN if dry eye; use lipid-containing products if evaporative symptoms. | Significant red painful eye/blurred vision must be referred. | Mild transient blur; no systemic DDIs. | Comfort within days and tear-film symptoms 1–2 weeks. |
26 | Hordeolum (stye) and chalazion
OTC conservative care · NOT separate BC MACS prescribing diagnosisSource: HEENT 16 Blepharitis & Eyelid Disorders, pages 14–22Risk factors / etiology
Chronic blepharitis, meibomian gland dysfunction/rosacea, cosmetic contamination, rubbing eyes, recurrent bacterial colonization.
Presentation / differential / complications
Hordeolum: acute tender localized red nodule of eyelid, external near lash follicle or internal tarsal gland; may drain. Chalazion: gradual, typically minimally painful sterile firm eyelid nodule from blocked meibomian gland. Complications: preseptal cellulitis, visual disturbance if large, rare recurrent lesion mimicking malignancy.
When to refer / scope limit
Same day: spreading erythema/fever, proptosis, impaired eye movement, pain with movement, visual change, photophobia, suspected orbital cellulitis. Routine referral if external hordeolum not improving in 2–3 days, internal within ~1 week, chalazion persists or recurs in same site (exclude malignancy).
Goals of therapy
Promote drainage and resolution, reduce pain/swelling, avoid unnecessary antibiotics or manipulation.
| Drug / category / scope | Strength • dose • frequency • duration | Contraindications / avoid / precautions | Adverse effects / important interactions | Monitoring and timing |
|---|---|---|---|---|
| Warm compress/massage (FIRST LINE) | 10–15 min per session, 3–4×/day; continue until resolved or reviewed (usually 1–2 weeks). | Avoid scalding the skin, aggressive pressure, home incision; urgent referral for orbital signs. | Temporary redness; no DDIs. | External stye review at 2–3 days; internal stye by 1 week; chalazion 1–2 weeks. |
| Acetaminophen (OTC) if pain | Adults 500–1000 mg PO q6–8h PRN, prudent max 3000 mg/day; 1–3 days only. | Liver disease, combination-product overdose. | Nausea/rare rash, hepatotoxicity at excessive doses. | Pain in 24–48 h; worsening pain warrants assessment. |
| Erythromycin 0.5% ophthalmic ointment (clinician-directed) | Not routine for uncomplicated chalazion/stye. Used when clinician identifies secondary infection or after incision (per lecture), dosing per procedure/label. | Allergy, do not use automatically for a sterile chalazion. | Temporary blurred vision, burning, allergy. | Reassessment after procedure or within 48 h if infection. |
| Systemic antibiotic / incision & drainage (clinician only) | Not indicated for simple isolated stye/chalazion; considered for spreading cellulitis or persistent lesion needing surgical drainage. | Never delay urgent assessment for orbital cellulitis signs. | Antibiotic-specific adverse effects and resistance; procedural risks. | Same-day clinician follow-up if spreading infection/visual symptoms. |
27 | Dry eye disease: episodic vs chronic
OTC lubricants · Rx specialist drugs NOT BC dry-eye MACSSource: HEENT 16 Dry Eye, pages 35–80Risk factors / etiology
Age, female sex/hormonal changes, contact lenses, prolonged screen use/reduced blink, smoking, air drafts, meibomian gland dysfunction/rosacea, Sjögren syndrome. Drug triggers: antihistamines, anticholinergics, oral decongestants, isotretinoin, diuretics, antidepressants.
Presentation / differential / complications
Tear-film instability, deficiency or excess evaporation → grittiness, burning, fluctuating blur, paradoxical watering, contact-lens discomfort, red irritated eyes; often worsens at end of day/screen use. Complications: corneal epithelial injury/keratitis, persistent pain and vision disturbance.
When to refer / scope limit
Urgent: true pain, photophobia, persistent blurred vision, corneal opacity, chemical injury, contact lens-related red eye, unusual unilateral discharge. Refer if persistent >5 days despite appropriate self-care, recurrent/chronic moderate–severe symptoms, suspected Sjögren (dry mouth + eyes), systemic disease, marked corneal signs.
Goals of therapy
Restore ocular comfort and stable tear film, reduce inflammation/evaporation and epithelial injury, preserve vision/function, minimize preservative toxicity.
| Drug / category / scope | Strength • dose • frequency • duration | Contraindications / avoid / precautions | Adverse effects / important interactions | Monitoring and timing |
|---|---|---|---|---|
| Carboxymethylcellulose sodium (CMC) artificial tears (OTC) | 0.5% or 1% (Refresh/Celluvisc examples): 1–2 drops affected eye TID–QID or as needed; may use preservative-free more frequently. | Avoid using contaminated multidose bottles; significant pain/photophobia needs referral. | Brief blur, stickiness, mild burning; few DDIs. | Comfort within minutes; reassess 3–5 days, and frequency/BAK exposure. |
| Hypromellose / hydroxypropyl methylcellulose (OTC) | 0.3% examples: 1–2 drops 3–4×/day or PRN; some gels longer duration. | Allergy and contamination; protect bottle tip. | More viscous options can blur vision and crust lashes. | Within minutes; check blur/tolerance at 3–5 days. |
| Polyvinyl alcohol / povidone (OTC) | PVA 1.4% or povidone ~1.25% per product: 1–2 drops 3–4×/day or PRN. | Avoid if preservative irritation; select PF for frequent dosing. | Transient stinging, blur. | Monitor comfort and total daily instillations over first week. |
| PEG 400 / propylene glycol / glycerin combinations (OTC) | E.g., PEG 400 0.4% + propylene glycol 0.3% (Systane type); 1–2 drops PRN up to several times/day according to product. | Ingredient-specific sensitivity; if severe painful red eye, refer. | Temporary blur/tingling; few DDIs. | Relief in minutes; evaluate persistent symptoms after 3–5 days. |
| Sodium hyaluronate 0.15% and lipid-enhanced drops (OTC) | Hyaluronate 0.15% examples: 1–2 drops PRN (often 3–6×/day); consider lipid-based drops for evaporative dryness. | Allergy, product compatibility with soft contacts per label. | Rare irritation, brief blur. | Review 3–7 days; match formulation to aqueous vs evaporative symptoms. |
| Night-time ocular gel/ointment (OTC) | Carbomer 0.2% gel or petrolatum/mineral oil ophthalmic ointment: small ribbon at bedtime if nighttime symptoms; follow exact ocular product directions. | Lanolin allergy in some ointments; do not use skin ointment in eye. | Long-lasting blurred vision, greasy lids; caution driving until vision clear. | Next-morning comfort within 3–5 days. |
| Cyclosporine 0.05% ophthalmic (Restasis, Rx outside MACS) | 1 drop each eye BID ongoing for chronic moderate–severe disease under clinician; response can take 3 weeks–3 months. | Active untreated ocular infection, drug allergy; separate other drops ≥15 min per product instructions. | Burning/stinging common; rare hypersensitivity; no meaningful systemic interactions. | Assess stinging during first 2 weeks; efficacy at 6–12 weeks. |
| Cyclosporine 0.09% ophthalmic (Cequa, Rx outside MACS) | 1 drop each eye BID ongoing under optometrist/ophthalmologist; not proven clearly superior to 0.05%. | Severe untreated eye infection, drug allergy; product instructions for contacts. | Instillation pain, conjunctival hyperemia; few systemic interactions. | Assess tolerability in 1–2 weeks; response 6–12 weeks. |
| Lifitegrast 5% ophthalmic (Xiidra, Rx outside MACS) | 1 drop each eye BID for chronic inflammatory dry eye; benefit may begin ~2 weeks, can take months. | Allergy, active unresolved infection/other serious eye disease; contacts removed per label. | Dysgeusia, eye irritation, transient blur; few systemic interactions. | Check early dysgeusia/comfort at 2 weeks; efficacy over 6–12 weeks. |
| Topical loteprednol ophthalmic (specialist-directed only) | Short-term ocular steroid course may precede cyclosporine in specialist regimens; no general OTC dose recommended. | Herpetic keratitis, fungal infection, increased IOP/glaucoma; requires slit-lamp/IOP monitoring. | Infection masking, ocular hypertension, cataract with prolonged use. | IOP and cornea monitored by eye-care specialist; not MACS dry-eye treatment. |
Sources, boundaries and verification
Lecture sources provided by user: GI 14 Oral Care (77 slides, Oct 2026), GI 09 Abdominal Gas (20 slides, Oct 2024), GI 11 GERD/Dyspepsia (69 slides, Oct 2026), GI 07 Nausea/Vomiting (62 slides, Oct 2026), GI 05 Constipation (54 slides, Oct 2026), GI 04 Diarrhea (28 slides, 2026). See page ranges noted at every chapter. Content is condensed and paraphrased; illustrative dosing is not exhaustive for every marketed formulation. Also used user-provided Acne.pdf (CPhA, 2022), HEENT 06 Sinusitis, HEENT 07 Allergic Rhinitis, HEENT 08 Pharyngitis, RESP 16 Cough and Cold, HEENT 15 Conjunctivitis, and HEENT 16 Blepharitis/Eyelid Disorders/Dry Eye.
Scope: BC Ministry of Health: Minor Ailments and Contraception Service and College: medication class limits. Schedule I medication must be in the permitted drug category for each listed ailment; the regulator does not supply a closed drug-by-drug list.
Selected verification: Health Canada dimenhydrinate labelling standard (adult/pediatric motion-sickness doses); Health Canada ranitidine NDMA restrictions and DIN status (some marketed, others cancelled); Canadian Transderm-V discontinuation notice; Health Canada Pepto-Bismol 262-mg product listing.
Important scope limitations: BC MACS prescribing assumes a low-risk minor presentation, confirmed within the pharmacist's competence without tests and short-term/episodic treatment. A drug listed as a specialist medication here does NOT thereby become independently prescribable for constipation, diarrhea or nausea. Hospital IV PONV dosing is not an outpatient counselling dose. Paediatric/renal/pregnancy regimens and prescriptions must be individualized; not all possible Canadian dosage forms/strengths are represented.
Additional clinical cross-checks (outside supplied lectures): CDC Group A Strep 2025 and Canadian Paediatric Society GAS statement (confirmation and dosing); Health Canada cough-and-cold medication risks in children; AAO 2026 contact lens infection risks. Drug strengths and availability vary by Canadian product; US doses are NOT automatically Canadian monograph directions.
Added lectures: MSK 07: Topical OTC Analgesics (2025), IID 16: UTI (Jan 2025), DERM 04/05: Lice & Scabies (2025), DERM 09: Rosacea (2025), DERM 12: Onychomycosis (2024), DERM 13: Atopic & Contact Dermatitis (2025). Page numbers in each section refer to those original sources.
Official BC MACS: College of Pharmacists of BC pharmacist-prescribing scope; BC Ministry of Health MACS conditions and drug classes; BC Pharmacy Association MACS drug categories. BCPhA Drug Products for Minor Ailments and Contraception list updated Mar 23, 2026 (non-exhaustive).
Known limits: Medication regimens given are adult teaching examples; high-risk populations, formulation-specific strengths, DINs, pregnancy/breastfeeding and renal function require current Canadian reference checking. Specialist-directed medications are shown for contrast and are not independently prescribable under a topical-only drug category. Older lecturer comments, prescribing status and drug availability may have changed.